I have heard horrible things about the treatment facilities in India and thus
would not recomend them.
The only company that has been sucessful in the treatment of the optic nerve is
Beike and they are located in China.
K

--- In stemcellsafety@yahoogroups.com, mazar L <mazar_9@...> wrote:
>
>
> Hi Kirshner,
>  
> Thank you for the information on stem cell treatment in India, If you could
write me the name of the hospital, name of the city where hospital located and
how good this hospital for
> stem cell treatmnet for optic nerve atriphy for adults, I appreciate your time
and help.
>  
> Thank you,
>  
> Regards,
> LN
>  
> --- On Sun, 3/1/09, Kirshner Ross-Vaden <kirsh@...> wrote:
>
> From: Kirshner Ross-Vaden <kirsh@...>
> Subject: [stemcellsafety] Stem Cell Tid Bit
> To: stemcellsafety@yahoogroups.com
> Date: Sunday, March 1, 2009, 9:54 AM
>
>
>
>
>
>
>
>
>  
> Stem Cells Revive Woman in Coma From Stroke
> In another event showing that Adult Stem Cell research in India is well ahead
of the
> curve, Repair Stem cells implanted into a woman in a coma from a brain stroke
have
> partially revived her. This stem cell therapy partially waking up a woman is
believed
> to be only the second time in history this has been done with stem cells.
> Two years ago, this woman suffered a brain stroke while in a hospital in
Sakaal , India . She had been in a coma
> ever since. Her husband approached a stem cell company in India and he asked
that she be implanted with her
> own stem cells taken from her bone marrow. The doctors agreed it could be done
and did it. (In Western cultures
> it would have taken years to get an “approval.�)
>

Hi, I'm new to the group. I'm taking care of my mother who is C4/C5
Incomplete. I wanted to know if anyone in this group has had stem cell
therapy, either adult stem cell or embroyic stem cell and what kind of
results they have had with the therapy. I'm researching going overseas
to get her the stem cell therapy. I'm seen so many confusing and
misleading things on the internet. Please, if anyone has had the
thearpy post back to the group and let me know if you were satisfied
with the results. Thank you.

Thank you for the response !  These types of discussions are good to
have since it respectively pushes us to go back to the literature.

Conceptually it seems easieer to beleive that an MSC would
differentiate into an oligodendrocyte than an hematopoietic lineage
cell..this is based on the publications....but i know that clinically
results are seen by the folks at Cellmedicine, as well as Beike in CP
patients with CD133s and CD34s....so it is interesting

below are some relevant abstracts for our discussion 1) MSC treating
MS in the rat model; 2) Fat stem cells treating rheumatoid arthritis;
3) fat stem cells treating crohn's....my only point is that it doesnt
necessarily have to be seen as a "scam"

  Glia. 2009 Feb 3. [Epub ahead of print] Links
Human bone marrow-derived mesenchymal stem cells induce Th2-polarized
immune response and promote endogenous repair in animal models of
multiple sclerosis.Bai L, Lennon DP, Eaton V, Maier K, Caplan AI,
Miller SD, Miller RH.
Case Western Reserve University, Centers for Stem Cells and
Regenerative Medicine, Translational Neuroscience, Department of
Neurosciences, Case School of Medicine, Cleveland, Ohio.

Cell-based therapies are attractive approaches to promote myelin
repair. Recent studies demonstrated a reduction in disease burden in
mice with experimental allergic encephalomyelitis (EAE) treated with
mouse mesenchymal stem cells (MSCs). Here, we demonstrated human bone
marrow-derived MSCs (BM-hMSCs) promote functional recovery in both
chronic and relapsing-remitting models of mouse EAE, traced their
migration into the injured CNS and assayed their ability to modulate
disease progression and the host immune response. Injected BM-hMSCs
accumulated in the CNS, reduced the extent of damage and increased
oligodendrocyte lineage cells in lesion areas. The increase in
oligodendrocytes in lesions may reflect BM-hMSC-induced changes in
neural fate determination, since neurospheres from treated animals
gave rise to more oligodendrocytes and less astrocytes than
nontreated neurospheres. Host immune responses were also influenced
by BM-hMSCs. Inflammatory T-cells including interferon gamma
producing Th1 cells and IL-17 producing Th17 inflammatory cells and
their associated cytokines were reduced along with concomitant
increases in IL-4 producing Th2 cells and anti-inflammatory
cytokines. Together, these data suggest that the BM-hMSCs represent a
viable option for therapeutic approaches. (c) 2009 Wiley-Liss, Inc.

  Ann Rheum Dis. 2009 Jan 5. [Epub ahead of print] Links
Human adipose-derived mesenchymal stem cells reduce inflammatory and
T-cell responses and induce regulatory T cells in vitro in rheumatoid
arthritis.Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-
Cortes P, Rico L, Büscher D, Delgado M.
School of Medicine, Seville University, Seville, Spain.

OBJECTIVES: Adult mesenchymal stem cells were recently found to
suppress effector T-cell and inflammatory responses and have emerged
as attractive therapeutic candidates for immune disorders. In
rheumatoid arthritis (RA), a loss in the immunological self-tolerance
causes the activation of autorreactive T cells against joint
components and subsequent chronic inflammation. The aim of this study
is to characterize the immunosuppresive activity of human adipose-
derived mesenchymal stem cells (hASCs) on collagen-reactive T cells
from RA patients. METHODS: We investigated the effects of hASCs on
collagen-reactive RA human T-cell proliferation and cytokine
production, as well as on the production of inflammatory mediators by
monocytes and fibroblast-like synoviocytes from RA patients. RESULTS:
hASCs suppressed antigen-specific response of T cells from RA
patients. hASCs inhibited the proliferative response and the
production of inflammatory cytokines by collagen-activated CD4 and
CD8 T cells. In contrast, the number of IL-10-producing T cells and
monocytes significantly augmented upon hASC-treatment. The
suppressive activity of hASCs was both cell-to-cell contact-dependent
and -independent. hASCs also stimulated the generation of FoxP3-
expressing CD4+CD25+ regulatory T cells with capacity to suppress
collagen-specific T-cell responses. Finally, hASCs donwregulated the
inflammatory response and the production of matrix-degrading enzymes
by synovial cells isolated from RA patients. CONCLUSIONS: Our work
identifies to hASCs as key regulators of immune tolerance with
capacity to suppress T-cell and inflammatory responses to induce the
generation/activation of antigen-specific regulatory T cells.









  Gastroenterology. 2008 Nov 27. [Epub ahead of print] Links
Adipose-Derived Mesenchymal Stem Cells Alleviate Experimental Colitis
by Inhibiting Inflammatory and Autoimmune Responses.González MA,
Gonzalez-Rey E, Rico L, Büscher D, Delgado M.
Cellerix SA, Tres Cantos (Madrid), Madrid; Fundación Centro Nacional
de Investigaciones Cardiovasculares Carlos III, Madrid.

BACKGROUND & AIMS: Crohn's disease is a chronic disease characterized
by severe T-helper (Th)1 cell-driven inflammation of the colon
partially caused by a loss of immune tolerance against mucosal
antigens. Mesenchymal stem cells were recently described to suppress
effector T-cell responses and have therapeutic effects in some immune
disorders. Here, we investigated the potential therapeutic effects of
human adipose-derived mesenchymal stem cells (hASCs) in a model of
inflammatory bowel disease. METHODS: Mice with trinitrobenzene
sulfonic acid-induced colitis were treated with hASCs after onset of
disease and clinical scores were evaluated. Inflammatory response was
determined by measuring the levels of different inflammatory
mediators in colon and serum. Th1-mediated effector responses were
evaluated by determining the proliferation and cytokine profile of
activated mesenteric lymph node cells. The number of regulatory T
cells and the suppressive capacity on Th1 cell responses was
determined. RESULTS: Systemic infusion of hASCs or murine ASCs
ameliorated the clinical and histopathologic severity of colitis,
abrogating body weight loss, diarrhea, and inflammation and
increasing survival (P < .001). This therapeutic effect was mediated
by down-regulating both Th1-driven autoimmune and inflammatory
responses. ASCs decreased a wide panel of inflammatory cytokines and
chemokines and increased interleukin-10 levels (P < .001), directly
acting on activated macrophages. hASCs also impaired Th1 cell
expansion and induced/activated CD4(+)CD25(+)FoxP3(+) regulatory T
cells with suppressive capacity on Th1 effector responses in vitro
and in vivo (P < .001). CONCLUSIONS: hASCs emerge as key regulators
of immune tolerance and as attractive candidates for a cell-based
therapy for Crohn's disease.



--- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@...> wrote:
>
> Yes CD 133 and 34 are found there but in very small numbers.  The
> largest number are found in umbilical cord stem cells.
> As I said the highest concentration of MSC's is found in bone
> marrow.  MSC's are also found in many other tissues as well but
what
> is critical is the concentraition.
> There is also only one study that has shown MSC's can effect white
> matter and that study was bumbed very soon after it was released
for
> faults in thier methods.  This was followed by another
that "proved"
> just the opposite which is to say that MSC's can not effect
mylien.
> There have also been several others that back that negitive one
up.
> The debate continues but as it stands now it does not appear MSC's
> effect white matter.
> As I said MSC's do seem to boost the other stem cells and yes this
is
> in part secondary to thier ability to regulate the immune
response.
> K
>
> --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> <thomas.ichim@> wrote:
> >
> > I have to respectfully disagree.  Well it does depend on how much
> > autologous adipose tissue is taken and readministered but...
> >
> > First of all, adipose tissue has high concentrations of
mesenchymal
> > stem cells, which are immune modulatory, as well as have ability
to
> > repair myelin.
> >
> > Secondly adipose tissue has high concentrations of M2 macrophages
> > which are antiinflammatory
> >
> > Thirdly, believe it or not (i didnt at first), adipose tissue has
> > both CD34 and CD133 cells ! weird !
> >
> > Forthly, adipose tissue has high concentrations of Treg cells
> >
> > below are some refernces...
> >
> >
> > 1. Kern, S., H. Eichler, J. Stoeve, H. Kluter, and K. Bieback.
> > 2006. Comparative analysis of mesenchymal stem cells from bone
> > marrow, umbilical cord blood, or adipose tissue. Stem Cells
24:1294-
> > 1301.
> > 2. Garcia-Olmo, D., M. Garcia-Arranz, D. Herreros, I. Pascual,
> > C. Peiro, and J. A. Rodriguez-Montes. 2005. A phase I clinical
> trial
> > of the treatment of Crohn's fistula by adipose mesenchymal stem
> cell
> > transplantation. Dis Colon Rectum 48:1416-1423.
> > 3. Stillaert, F. B., C. Di Bartolo, J. A. Hunt, N. P. Rhodes, E.
> > Tognana, S. Monstrey, and P. N. Blondeel. 2008. Human clinical
> > experience with adipose precursor cells seeded on hyaluronic acid-
> > based spongy scaffolds. Biomaterials 29:3953-3959.
> > 4. Garcia-Olmo, D., M. Garcia-Arranz, and D. Herreros. 2008.
> > Expanded adipose-derived stem cells for the treatment of complex
> > perianal fistula including Crohn's disease. Expert Opin Biol Ther
> > 8:1417-1423.
> > 5. Fang, B., Y. P. Song, L. M. Liao, Q. Han, and R. C. Zhao.
> > 2006. Treatment of severe therapy-resistant acute graft-versus-
host
> > disease with human adipose tissue-derived mesenchymal stem cells.
> > Bone Marrow Transplant 38:389-390.
> > 6. Fang, B., Y. Song, R. C. Zhao, Q. Han, and Q. Lin. 2007.
> > Using human adipose tissue-derived mesenchymal stem cells as
> salvage
> > therapy for hepatic graft-versus-host disease resembling acute
> > hepatitis. Transplant Proc 39:1710-1713.
> > 7. Fang, B., Y. Song, L. Liao, Y. Zhang, and R. C. Zhao. 2007.
> > Favorable response to human adipose tissue-derived mesenchymal
stem
> > cells in steroid-refractory acute graft-versus-host disease.
> > Transplant Proc 39:3358-3362.
> > 8. Hayashi, O., Y. Katsube, M. Hirose, H. Ohgushi, and H. Ito.
> > 2008. Comparison of osteogenic ability of rat mesenchymal stem
> cells
> > from bone marrow, periosteum, and adipose tissue. Calcif Tissue
Int
> > 82:238-247.
> > 9. Noel, D., D. Caton, S. Roche, C. Bony, S. Lehmann, L.
> > Casteilla, C. Jorgensen, and B. Cousin. 2008. Cell specific
> > differences between human adipose-derived and mesenchymal-stromal
> > cells despite similar differentiation potentials. Exp Cell Res
> > 314:1575-1584.
> > 10. Kim, Y., H. Kim, H. Cho, Y. Bae, K. Suh, and J. Jung. 2007.
> > Direct comparison of human mesenchymal stem cells derived from
> > adipose tissues and bone marrow in mediating neovascularization
in
> > response to vascular ischemia. Cell Physiol Biochem 20:867-876.
> > 11. Keyser, K. A., K. E. Beagles, and H. P. Kiem. 2007.
> > Comparison of mesenchymal stem cells from different tissues to
> > suppress T-cell activation. Cell Transplant 16:555-562.
> > 12. www.vet-stem.com.
> > 13. Black, L. L., J. Gaynor, D. Gahring, C. Adams, D. Aron, S.
> > Harman, D. A. Gingerich, and R. Harman. 2007. Effect of adipose-
> > derived mesenchymal stem and regenerative cells on lameness in
dogs
> > with chronic osteoarthritis of the coxofemoral joints: a
> randomized,
> > double-blinded, multicenter, controlled trial. Vet Ther 8:272-284.
> > 14. Black, L. L., J. Gaynor, C. Adams, S. Dhupa, A. E. Sams, R.
> > Taylor, S. Harman, D. A. Gingerich, and R. Harman. 2008. Effect
of
> > intraarticular injection of autologous adipose-derived
mesenchymal
> > stem and regenerative cells on clinical signs of chronic
> > osteoarthritis of the elbow joint in dogs. Vet Ther 9:192-200.
> > 15. Lin, K., Y. Matsubara, Y. Masuda, K. Togashi, T. Ohno, T.
> > Tamura, Y. Toyoshima, K. Sugimachi, M. Toyoda, H. Marc, and A.
> > Douglas. 2008. Characterization of adipose tissue-derived cells
> > isolated with the Celution system. Cytotherapy 10:417-426.
> > 16. http://www.tissuegenesis.com/TGI%201000%20Product%
> > 20Brochure.pdf.
> > 17. Hang-Fu, L., G. Marmolya, and D. H. Feiglin. 1995.
> > Liposuction fat-fillant implant for breast augmentation and
> > reconstruction. Aesthetic Plast Surg 19:427-437.
> > 18. Klein, A. W. 2001. Skin filling. Collagen and other
> > injectables of the skin. Dermatol Clin 19:491-508, ix.
> > 19. Hollenberg, C. H., and A. Vost. 1969. Regulation of DNA
> > synthesis in fat cells and stromal elements from rat adipose
> tissue.
> > J Clin Invest 47:2485-2498.
> > 20. Gaben-Cogneville, A. M., Y. Aron, G. Idriss, T. Jahchan, J.
> > Y. Pello, and E. Swierczewski. 1983. Differentiation under the
> > control of insulin of rat preadipocytes in primary culture.
> Isolation
> > of homogeneous cellular fractions by gradient centrifugation.
> Biochim
> > Biophys Acta 762:437-444.
> > 21. Glick, J. M., and S. J. Adelman. 1983. Established cell lines
> > from rat adipose tissue that secrete lipoprotein lipase. In Vitro
> > 19:421-428.
> > 22. Zuk, P. A., M. Zhu, H. Mizuno, J. Huang, J. W. Futrell, A. J.
> > Katz, P. Benhaim, H. P. Lorenz, and M. H. Hedrick. 2001.
> Multilineage
> > cells from human adipose tissue: implications for cell-based
> > therapies. Tissue Eng 7:211-228.
> > 23. Zuk, P. A., M. Zhu, P. Ashjian, D. A. De Ugarte, J. I. Huang,
> > H. Mizuno, Z. C. Alfonso, J. K. Fraser, P. Benhaim, and M. H.
> > Hedrick. 2002. Human adipose tissue is a source of multipotent
stem
> > cells. Mol Biol Cell 13:4279-4295.
> > 24. Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der
> > Zee, T. Li, B. Witzenbichler, G. Schatteman, and J. M. Isner.
1997.
> > Isolation of putative progenitor endothelial cells for
> angiogenesis.
> > Science 275:964-967.
> > 25. Rauscher, F. M., P. J. Goldschmidt-Clermont, B. H. Davis, T.
> > Wang, D. Gregg, P. Ramaswami, A. M. Pippen, B. H. Annex, C. Dong,
> and
> > D. A. Taylor. 2003. Aging, progenitor cell exhaustion, and
> > atherosclerosis. Circulation 108:457-463.
> > 26. Sata, M., D. Fukuda, K. Tanaka, Y. Kaneda, H. Yashiro, and I.
> > Shirakawa. 2005. The role of circulating precursors in vascular
> > repair and lesion formation. J Cell Mol Med 9:557-568.
> > 27. Miranville, A., C. Heeschen, C. Sengenes, C. A. Curat, R.
> > Busse, and A. Bouloumie. 2004. Improvement of postnatal
> > neovascularization by human adipose tissue-derived stem cells.
> > Circulation 110:349-355.
> > 28. Urbich, C., and S. Dimmeler. 2005. Risk factors for coronary
> > artery disease, circulating endothelial progenitor cells, and the
> > role of HMG-CoA reductase inhibitors. Kidney Int 67:1672-1676.
> > 29. Planat-Benard, V., J. S. Silvestre, B. Cousin, M. Andre, M.
> > Nibbelink, R. Tamarat, M. Clergue, C. Manneville, C. Saillan-
> Barreau,
> > M. Duriez, A. Tedgui, B. Levy, L. Penicaud, and L. Casteilla.
2004.
> > Plasticity of human adipose lineage cells toward endothelial
cells:
> > physiological and therapeutic perspectives. Circulation 109:656-
663.
> > 30. Rehman, J., D. Traktuev, J. Li, S. Merfeld-Clauss, C. J. Temm-
> > Grove, J. E. Bovenkerk, C. L. Pell, B. H. Johnstone, R. V.
> Considine,
> > and K. L. March. 2004. Secretion of angiogenic and antiapoptotic
> > factors by human adipose stromal cells. Circulation 109:1292-1298.
> > 31. Cai, L., B. H. Johnstone, T. G. Cook, Z. Liang, D. Traktuev,
> > K. Cornetta, D. A. Ingram, E. D. Rosen, and K. L. March. 2007.
> > Suppression of hepatocyte growth factor production impairs the
> > ability of adipose-derived stem cells to promote ischemic tissue
> > revascularization. Stem Cells 25:3234-3243.
> > 32. Sumi, M., M. Sata, N. Toya, K. Yanaga, T. Ohki, and R. Nagai.
> > 2007. Transplantation of adipose stromal cells, but not mature
> > adipocytes, augments ischemia-induced angiogenesis. Life Sci
80:559-
> > 565.
> > 33. Minana, M. D., F. Carbonell-Uberos, V. Mirabet, S. Marin, and
> > A. Encabo. 2008. IFATS collection: Identification of
hemangioblasts
> > in the adult human adipose tissue. Stem Cells 26:2696-2704.
> > 34. Astori, G., F. Vignati, S. Bardelli, M. Tubio, M. Gola, V.
> > Albertini, F. Bambi, G. Scali, D. Castelli, V. Rasini, G.
Soldati,
> > and T. Moccetti. 2007. "In vitro" and multicolor phenotypic
> > characterization of cell subpopulations identified in fresh human
> > adipose tissue stromal vascular fraction and in the derived
> > mesenchymal stem cells. J Transl Med 5:55.
> > 35. Varma, M. J., R. G. Breuls, T. E. Schouten, W. J. Jurgens, H.
> > J. Bontkes, G. J. Schuurhuis, S. M. van Ham, and F. J. van
> Milligen.
> > 2007. Phenotypical and functional characterization of freshly
> > isolated adipose tissue-derived stem cells. Stem Cells Dev 16:91-
> 104.
> > 36. Ruhnke, M., H. Ungefroren, A. Nussler, F. Martin, M.
> > Brulport, W. Schormann, J. G. Hengstler, W. Klapper, K. Ulrichs,
J.
> > A. Hutchinson, B. Soria, R. M. Parwaresch, P. Heeckt, B. Kremer,
> and
> > F. Fandrich. 2005. Differentiation of in vitro-modified human
> > peripheral blood monocytes into hepatocyte-like and pancreatic
> islet-
> > like cells. Gastroenterology 128:1774-1786.
> > 37. Ruhnke, M., A. K. Nussler, H. Ungefroren, J. G. Hengstler, B.
> > Kremer, W. Hoeckh, T. Gottwald, P. Heeckt, and F. Fandrich. 2005.
> > Human monocyte-derived neohepatocytes: a promising alternative to
> > primary human hepatocytes for autologous cell therapy.
> > Transplantation 79:1097-1103.
> > 38. Suganami, T., J. Nishida, and Y. Ogawa. 2005. A paracrine
> > loop between adipocytes and macrophages aggravates inflammatory
> > changes: role of free fatty acids and tumor necrosis factor
alpha.
> > Arterioscler Thromb Vasc Biol 25:2062-2068.
> > 39. Bastard, J. P., M. Maachi, C. Lagathu, M. J. Kim, M. Caron,
> > H. Vidal, J. Capeau, and B. Feve. 2006. Recent advances in the
> > relationship between obesity, inflammation, and insulin
resistance.
> > Eur Cytokine Netw 17:4-12.
> > 40. Zeyda, M., and T. M. Stulnig. 2007. Adipose tissue
> > macrophages. Immunol Lett 112:61-67.
> > 41. Odegaard, J. I., R. R. Ricardo-Gonzalez, M. H. Goforth, C. R.
> > Morel, V. Subramanian, L. Mukundan, A. R. Eagle, D. Vats, F.
> > Brombacher, A. W. Ferrante, and A. Chawla. 2007. Macrophage-
> specific
> > PPARgamma controls alternative activation and improves insulin
> > resistance. Nature 447:1116-1120.
> > 42. Zeyda, M., D. Farmer, J. Todoric, O. Aszmann, M. Speiser, G.
> > Gyori, G. J. Zlabinger, and T. M. Stulnig. 2007. Human adipose
> tissue
> > macrophages are of an anti-inflammatory phenotype but capable of
> > excessive pro-inflammatory mediator production. Int J Obes (Lond)
> > 31:1420-1428.
> > 43. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A.
> > Sica. 2002. Macrophage polarization: tumor-associated macrophages
> as
> > a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol
> > 23:549-555.
> > 44. Mehta, A., R. Brewington, M. Chatterji, M. Zoubine, G. T.
> > Kinasewitz, G. T. Peer, A. C. Chang, F. B. Taylor, Jr., and A.
> > Shnyra. 2004. Infection-induced modulation of m1 and m2
phenotypes
> in
> > circulating monocytes: role in immune monitoring and early
> prognosis
> > of sepsis. Shock 22:423-430.
> > 45. Song, G. Y., C. S. Chung, D. Jarrar, I. H. Chaudry, and A.
> > Ayala. 2001. Evolution of an immune suppressive macrophage
> phenotype
> > as a product of P38 MAPK activation in polymicrobial sepsis.
Shock
> > 15:42-48.
> > 46. Gustafsson, C., J. Mjosberg, A. Matussek, R. Geffers, L.
> > Matthiesen, G. Berg, S. Sharma, J. Buer, and J. Ernerudh. 2008.
> Gene
> > expression profiling of human decidual macrophages: evidence for
> > immunosuppressive phenotype. PLoS ONE 3:e2078.
> > 47. Wang, Y., Y. P. Wang, G. Zheng, V. W. Lee, L. Ouyang, D. H.
> > Chang, D. Mahajan, J. Coombs, Y. M. Wang, S. I. Alexander, and D.
> C.
> > Harris. 2007. Ex vivo programmed macrophages ameliorate
> experimental
> > chronic inflammatory renal disease. Kidney Int 72:290-299.
> > 48. Ponomarev, E. D., K. Maresz, Y. Tan, and B. N. Dittel. 2007.
> > CNS-derived interleukin-4 is essential for the regulation of
> > autoimmune inflammation and induces a state of alternative
> activation
> > in microglial cells. J Neurosci 27:10714-10721.
> > 49. Zhang, X., M. Li, D. Lian, X. Zheng, Z. X. Zhang, T. E.
> > Ichim, X. Xia, X. Huang, C. Vladau, M. Suzuki, B. Garcia, A. M.
> > Jevnikar, and W. P. Min. 2008. Generation of therapeutic
dendritic
> > cells and regulatory T cells for preventing allogeneic cardiac
> graft
> > rejection. Clin Immunol 127:313-321.
> > 50. Ichim, T. E., R. Zhong, and W. P. Min. 2003. Prevention of
> > allograft rejection by in vitro generated tolerogenic dendritic
> > cells. Transpl Immunol 11:295-306.
> > 51. Tiemessen, M. M., A. L. Jagger, H. G. Evans, M. J. van
> > Herwijnen, S. John, and L. S. Taams. 2007. CD4+CD25+Foxp3+
> regulatory
> > T cells induce alternative activation of human
> monocytes/macrophages.
> > Proc Natl Acad Sci U S A 104:19446-19451.
> > 52. Ryan, J. M., F. Barry, J. M. Murphy, and B. P. Mahon. 2007.
> > Interferon-gamma does not break, but promotes the
immunosuppressive
> > capacity of adult human mesenchymal stem cells. Clin Exp Immunol
> > 149:353-363.
> > 53. Ye, Z., Y. Wang, H. Y. Xie, and S. S. Zheng. 2008.
> > Immunosuppressive effects of rat mesenchymal stem cells:
> involvement
> > of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int
> 7:608-
> > 614.
> > 54. Askenasy, N., A. Kaminitz, and S. Yarkoni. 2008. Mechanisms
> > of T regulatory cell function. Autoimmun Rev 7:370-375.
> > 55. Gonzalez-Rey, E., M. A. Gonzalez, N. Varela, F. O'Valle, P.
> > Hernandez-Cortes, L. Rico, D. Buscher, and M. Delgado. 2009.
Human
> > adipose-derived mesenchymal stem cells reduce inflammatory and T-
> cell
> > responses and induce regulatory T cells in vitro in rheumatoid
> > arthritis. Ann Rheum Dis.
> > 56. Casiraghi, F., N. Azzollini, P. Cassis, B. Imberti, M.
> > Morigi, D. Cugini, R. A. Cavinato, M. Todeschini, S. Solini, A.
> > Sonzogni, N. Perico, G. Remuzzi, and M. Noris. 2008.
Pretransplant
> > infusion of mesenchymal stem cells prolongs the survival of a
> > semiallogeneic heart transplant through the generation of
> regulatory
> > T cells. J Immunol 181:3933-3946.
> > 57. Di Ianni, M., B. Del Papa, M. De Ioanni, L. Moretti, E.
> > Bonifacio, D. Cecchini, P. Sportoletti, F. Falzetti, and A.
> Tabilio.
> > 2008. Mesenchymal cells recruit and regulate T regulatory cells.
> Exp
> > Hematol 36:309-318.
> > 58. Zannettino, A. C., S. Paton, A. Arthur, F. Khor, S. Itescu,
> > J. M. Gimble, and S. Gronthos. 2008. Multipotential human adipose-
> > derived stromal stem cells exhibit a perivascular phenotype in
> vitro
> > and in vivo. J Cell Physiol 214:413-421.
> > 59. Hoogduijn, M. J., M. J. Crop, A. M. Peeters, G. J. Van Osch,
> > A. H. Balk, J. N. Ijzermans, W. Weimar, and C. C. Baan. 2007.
Human
> > heart, spleen, and perirenal fat-derived mesenchymal stem cells
> have
> > immunomodulatory capacities. Stem Cells Dev 16:597-604.
> > 60. Chao, K. C., K. F. Chao, Y. S. Fu, and S. H. Liu. 2008. Islet-
> > like clusters derived from mesenchymal stem cells in Wharton's
> Jelly
> > of the human umbilical cord for transplantation to control type 1
> > diabetes. PLoS ONE 3:e1451.
> > 61. Jo, Y. Y., H. J. Lee, S. Y. Kook, H. W. Choung, J. Y. Park,
> > J. H. Chung, Y. H. Choung, E. S. Kim, H. C. Yang, and P. H.
Choung.
> > 2007. Isolation and characterization of postnatal stem cells from
> > human dental tissues. Tissue Eng 13:767-773.
> > 62. He, Q., C. Wan, and G. Li. 2007. Concise review: multipotent
> > mesenchymal stromal cells in blood. Stem Cells 25:69-77.
> > 63. Djouad, F., L. M. Charbonnier, C. Bouffi, P. Louis-Plence, C.
> > Bony, F. Apparailly, C. Cantos, C. Jorgensen, and D. Noel. 2007.
> > Mesenchymal stem cells inhibit the differentiation of dendritic
> cells
> > through an interleukin-6-dependent mechanism. Stem Cells 25:2025-
> 2032.
> > 64. English, K., F. P. Barry, and B. P. Mahon. 2008. Murine
> > mesenchymal stem cells suppress dendritic cell migration,
> maturation
> > and antigen presentation. Immunol Lett 115:50-58.
> > 65. Nemeth, K., A. Leelahavanichkul, P. S. Yuen, B. Mayer, A.
> > Parmelee, K. Doi, P. G. Robey, K. Leelahavanichkul, B. H. Koller,
> J.
> > M. Brown, X. Hu, I. Jelinek, R. A. Star, and E. Mezey. 2009. Bone
> > marrow stromal cells attenuate sepsis via prostaglandin E(2)-
> > dependent reprogramming of host macrophages to increase their
> > interleukin-10 production. Nat Med 15:42-49.
> > 66. Ortiz, L. A., M. Dutreil, C. Fattman, A. C. Pandey, G.
> > Torres, K. Go, and D. G. Phinney. 2007. Interleukin 1 receptor
> > antagonist mediates the antiinflammatory and antifibrotic effect
of
> > mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S
A
> > 104:11002-11007.
> > 67. Nasef, A., A. Chapel, C. Mazurier, S. Bouchet, M. Lopez, N.
> > Mathieu, L. Sensebe, Y. Zhang, N. C. Gorin, D. Thierry, and L.
> > Fouillard. 2007. Identification of IL-10 and TGF-beta transcripts
> > involved in the inhibition of T-lymphocyte proliferation during
> cell
> > contact with human mesenchymal stem cells. Gene Expr 13:217-226.
> > 68. Karussis, D., and I. Kassis. 2008. The potential use of stem
> > cells in multiple sclerosis: an overview of the preclinical
> > experience. Clin Neurol Neurosurg 110:889-896.
> > 69. Zappia, E., S. Casazza, E. Pedemonte, F. Benvenuto, I.
> > Bonanni, E. Gerdoni, D. Giunti, A. Ceravolo, F. Cazzanti, F.
> > Frassoni, G. Mancardi, and A. Uccelli. 2005. Mesenchymal stem
cells
> > ameliorate experimental autoimmune encephalomyelitis inducing T-
> cell
> > anergy. Blood 106:1755-1761.
> > 70. Boumaza, I., S. Srinivasan, W. T. Witt, C. Feghali-Bostwick,
> > Y. Dai, A. Garcia-Ocana, and M. Feili-Hariri. 2008. Autologous
bone
> > marrow-derived rat mesenchymal stem cells promote PDX-1 and
insulin
> > expression in the islets, alter T cell cytokine pattern and
> preserve
> > regulatory T cells in the periphery and induce sustained
> > normoglycemia. J Autoimmun.
> > 71. Zhou, K., H. Zhang, O. Jin, X. Feng, G. Yao, Y. Hou, and L.
> > Sun. 2008. Transplantation of human bone marrow mesenchymal stem
> cell
> > ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol
> > Immunol 5:417-424.
> > 72. Parekkadan, B., A. W. Tilles, and M. L. Yarmush. 2008. Bone
> > marrow-derived mesenchymal stem cells ameliorate autoimmune
> > enteropathy independently of regulatory T cells. Stem Cells
26:1913-
> > 1919.
> > 73. Arthur, A., A. Zannettino, and S. Gronthos. 2009. The
> > therapeutic applications of multipotential mesenchymal/stromal
stem
> > cells in skeletal tissue repair. J Cell Physiol 218:237-245.
> > 74. Mishra, P. K. 2008. Bone marrow-derived mesenchymal stem
> > cells for treatment of heart failure: is it all paracrine actions
> and
> > immunomodulation? J Cardiovasc Med (Hagerstown) 9:122-128.
> > 75. Centeno, C. J., D. Busse, J. Kisiday, C. Keohan, M. Freeman,
> > and D. Karli. 2008. Increased knee cartilage volume in
degenerative
> > joint disease using percutaneously implanted, autologous
> mesenchymal
> > stem cells. Pain Physician 11:343-353.
> > 76. Katritsis, D. 2008. Cellular replacement therapy for
> > arrhythmia treatment: early clinical experience. J Interv Card
> > Electrophysiol 22:99-105.
> > 77. Slavin, S., B. G. Kurkalli, and D. Karussis. 2008. The
> > potential use of adult stem cells for the treatment of multiple
> > sclerosis and other neurodegenerative disorders. Clin Neurol
> > Neurosurg 110:943-946.
> > 78. Rosati, G. 2001. The prevalence of multiple sclerosis in the
> > world: an update. Neurol Sci 22:117-139.
> > 79. Pittock, S. J., and C. F. Lucchinetti. 2007. The pathology of
> > MS: new insights and potential clinical applications. Neurologist
> > 13:45-56.
> > 80. Saresella, M., I. Marventano, R. Longhi, F. Lissoni, D.
> > Trabattoni, L. Mendozzi, D. Caputo, and M. Clerici. 2008.
> > CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable
> relapsing-
> > remitting multiple sclerosis and their modulation by therapy.
FASEB
> J
> > 22:3500-3508.
> > 81. Korporal, M., J. Haas, B. Balint, B. Fritzsching, A. Schwarz,
> > S. Moeller, B. Fritz, E. Suri-Payer, and B. Wildemann. 2008.
> > Interferon beta-induced restoration of regulatory T-cell function
> in
> > multiple sclerosis is prompted by an increase in newly generated
> > naive regulatory T cells. Arch Neurol 65:1434-1439.
> > 82. Akirav, E. M., C. M. Bergman, M. Hill, and N. H. Ruddle.
> > 2009. Depletion of CD4(+)CD25(+) T cells exacerbates experimental
> > autoimmune encephalomyelitis induced by mouse, but not rat,
> antigens.
> > J Neurosci Res.
> > 83. Reddy, J., Z. Illes, X. Zhang, J. Encinas, J. Pyrdol, L.
> > Nicholson, R. A. Sobel, K. W. Wucherpfennig, and V. K. Kuchroo.
> 2004.
> > Myelin proteolipid protein-specific CD4+CD25+ regulatory cells
> > mediate genetic resistance to experimental autoimmune
> > encephalomyelitis. Proc Natl Acad Sci U S A 101:15434-15439.
> > 84. Gregg, C., V. Shikar, P. Larsen, G. Mak, A. Chojnacki, V. W.
> > Yong, and S. Weiss. 2007. White matter plasticity and enhanced
> > remyelination in the maternal CNS. J Neurosci 27:1812-1823.
> > 85. Penner, I. K., L. Kappos, M. Rausch, K. Opwis, and E. W.
> > Radu. 2006. Therapy-induced plasticity of cognitive functions in
MS
> > patients: insights from fMRI. J Physiol Paris 99:455-462.
> > 86. Nait-Oumesmar, B., N. Picard-Riera, C. Kerninon, L. Decker,
> > D. Seilhean, G. U. Hoglinger, E. C. Hirsch, R. Reynolds, and A.
> Baron-
> > Van Evercooren. 2007. Activation of the subventricular zone in
> > multiple sclerosis: evidence for early glial progenitors. Proc
Natl
> > Acad Sci U S A 104:4694-4699.
> > 87. Kassis, I., N. Grigoriadis, B. Gowda-Kurkalli, R. Mizrachi-
> > Kol, T. Ben-Hur, S. Slavin, O. Abramsky, and D. Karussis. 2008.
> > Neuroprotection and immunomodulation with mesenchymal stem cells
in
> > chronic experimental autoimmune encephalomyelitis. Arch Neurol
> 65:753-
> > 761.
> > 88. Bai, L., D. P. Lennon, V. Eaton, K. Maier, A. I. Caplan, S.
> > D. Miller, and R. H. Miller. 2009. Human bone marrow-derived
> > mesenchymal stem cells induce Th2-polarized immune response and
> > promote endogenous repair in animal models of multiple sclerosis.
> > Glia.
> > 89. Mohyeddin Bonab, M., S. Yazdanbakhsh, J. Lotfi, K.
> > Alimoghaddom, F. Talebian, F. Hooshmand, A. Ghavamzadeh, and B.
> > Nikbin. 2007. Does mesenchymal stem cell therapy help multiple
> > sclerosis patients? Report of a pilot study. Iran J Immunol 4:50-
57.
> > 90. Martino, G., R. Furlan, E. Brambilla, A. Bergami, F. Ruffini,
> > M. Gironi, P. L. Poliani, L. M. Grimaldi, and G. Comi. 2000.
> > Cytokines and immunity in multiple sclerosis: the dual signal
> > hypothesis. J Neuroimmunol 109:3-9.
> > 91. Hafler, D. A., J. M. Slavik, D. E. Anderson, K. C. O'Connor,
> > P. De Jager, and C. Baecher-Allan. 2005. Multiple sclerosis.
> Immunol
> > Rev 204:208-231.
> > 92. Viglietta, V., C. Baecher-Allan, H. L. Weiner, and D. A.
> > Hafler. 2004. Loss of functional suppression by CD4+CD25+
> regulatory
> > T cells in patients with multiple sclerosis. J Exp Med 199:971-
979.
> > 93. Kornek, B., and H. Lassmann. 2003. Neuropathology of multiple
> > sclerosis-new concepts. Brain Res Bull 61:321-326.
> > 94. Kornek, B., M. K. Storch, R. Weissert, E. Wallstroem, A.
> > Stefferl, T. Olsson, C. Linington, M. Schmidbauer, and H.
Lassmann.
> > 2000. Multiple sclerosis and chronic autoimmune
encephalomyelitis:
> a
> > comparative quantitative study of axonal injury in active,
> inactive,
> > and remyelinated lesions. Am J Pathol 157:267-276.
> >
> >
> >
> >
> >
> > --- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@>
wrote:
> > >
> > > I was referring to stem cells taken from Adipose tissue which
is
> > > being used to treat many diagnosis'.  I use the word "treat"
> > lightly.
> > > Do you remember a few years ago when it all began...shark stem
> > cells
> > > being given to humans for an array of issues.  Then came the
pigs.
> > > There is no evidence to lead one to think adipose stem cells
will
> > > improve any disorder much less one as complex as MS which
> involves
> > > the brain and the entire nervous system of the body.  What MS
> > > patients need are partcular subset of stem cells namely CD1333
> and
> > > CD34.  For best results boost these with MSC's which are found
in
> > the
> > > highest concentraition in the bone marrow.
> > > K
> > >
> > > --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> > > <thomas.ichim@> wrote:
> > > >
> > > > Are you talking about autologous fat for crohn's being
a "fad"?
> > > >
> > > > or about Costa Rica?
> > > >
> > > >
> > > >
> > > > --- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@>
> > wrote:
> > > > >
> > > > > There are "fads" even in the stem cell world and this is an
> > > example
> > > > > of yet another treatment designed to line the pockets.
This
> > > > > treatment was created a couple of years ago but not much
has
> > been
> > > > > reported about it because it has shown so little promise.
> > > > > Buyer beware.
> > > > >
> > > > > --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> > > > > <thomas.ichim@> wrote:
> > > > > >
> > > > > > did you guys see they also are doing autologous fat for
MS
> in
> > > > Costa
> > > > > > Rica?
> > > > > >
> > > > > > http://www.youtube.com/watch?v=k3Z1J3QmYoE
> > > > > >
> > > > > >
> > > > > >
> > > > > > --- In stemcellsafety@yahoogroups.com, "Kirshner Ross-
> Vaden"
> > > > > > <kirsh@> wrote:
> > > > > > >
> > > > > > >
> > > > > > > Stem Cell Treatment For Crohn's Disease
> > > > > > >
> > > > > > >
> > > > > > > Article Date: 21 Feb 2009 - 0:00 PST
> > > > > > >
> > > > > > >
> > > > > > >
> > > > > > >   _____
> > > > > > >
> > > > > > >
> > > > > > > Cellular therapy with stem cells
> > > > > > >
> > > > > >
> > > > >
> > > >
> > >
> >
>
<http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>
> > > > > >  is
> > > > > > > revolutionizing the focus of treatment of many serious
> > > > diseases.
> > > > > > Replacing
> > > > > > > the cells of damaged tissue with other new cells from
the
> > > same
> > > > > > patient is
> > > > > > > already a reality. This is the basis of cellular
therapy
> > and
> > > > > > regenerative
> > > > > > > medicine, the latest great advance in biomedicine. In
> this
> > > > line,
> > > > > > Hospital
> > > > > > > Clínic, Barcelona is leading the world in the
application
> > of
> > > an
> > > > > > innovative
> > > > > > > cellular therapy that uses stem cells to treat Crohn's
> > > disease,
> > > > a
> > > > > > chronic
> > > > > > > genetic disease that affects 1% of the population in
> Spain
> > > and
> > > > > > which has
> > > > > > > considerable impact on the quality of life of the
> patients.
> > > The
> > > > > > procedure is
> > > > > > > based on an autologous bone-marrow transplant (when
> > patients
> > > > > > receive a
> > > > > > > transplant of their own stem cells) and now constitutes
a
> > > > > treatment
> > > > > > option
> > > > > > > to cure an intestinal disease that sometimes does not
> > > > > successfully
> > > > > > respond
> > > > > > > to drugs and requires highly complex surgery that does
> not
> > > > > provide
> > > > > > a cure.
> > > > > > >
> > > > > > > Hospital Clínic, Barcelona is one of the few hospitals
in
> > the
> > > > > world
> > > > > > to apply
> > > > > > > this new therapeutic option for patients with Crohn's
> > > disease,
> > > > > and
> > > > > > it does
> > > > > > > so with the guarantee of success experienced in the US
> and
> > > > Italy,
> > > > > > where the
> > > > > > > technique has been tested with excellent results: in an
> > > average
> > > > > > follow-up
> > > > > > > period of 6 years, 80% of transplant patients are in a
> > phase
> > > of
> > > > > > total
> > > > > > > remission of the disease and the remaining 20% have
shown
> > > > > > considerable
> > > > > > > improvement following the transplant, and are now
> > responding
> > > > > > favorably to
> > > > > > > drugs. Dr. Julián Panés and Dr. Elena Ricart over the
> > > > > > Gastroenterology
> > > > > > > Department of Hospital Clínic, Barcelona are the
driving
> > > force
> > > > > > behind this
> > > > > > > therapy in Spain and began to implement regenerative
> > cellular
> > > > > > therapy in
> > > > > > > patients with Crohn's disease in August 2008. To date,
a
> > > total
> > > > of
> > > > > 6
> > > > > > patients
> > > > > > > are benefiting from this new treatment, of whom 3 I've
> > > already
> > > > > > completed the
> > > > > > > process and are in the follow-up face, and a further 3
> are
> > at
> > > > > > different
> > > > > > > stages of therapy. The transplant requires several
weeks
> of
> > > > > > admission to
> > > > > > > hospital before patients receive their own cells.
> > > > > > >
> > > > > > > The success of autologous stem-cell transplants in
> Crohn's
> > > > > disease
> > > > > > is
> > > > > > > possible thanks to the joint collaboration of the
> > > > > gastroenterology
> > > > > > and
> > > > > > > hematology departments and of the hemotherapy and
> > hemostasis
> > > > > > department, as
> > > > > > > the procedure is the same as that carried out in bone-
> > morrow
> > > > > > transplants to
> > > > > > > cure leukemia or myeloma. Thus, when a case is
detected,
> > the
> > > > > > professionals
> > > > > > > from the different departments of Hospital Clinic,
> > Barcelona
> > > > > > supervise each
> > > > > > > of the phases of the process to autologous Transplant.
In
> > > this
> > > > > > case, Dr.
> > > > > > > Panés and Dr. Ricart from the gastroenterology
department
> > > work
> > > > > > together with
> > > > > > > Dr. Montserrat Rovira from the hematology department of
> the
> > > > > Catalan
> > > > > > hospital
> > > > > > > and with Dr. Enric Carreras, the head of this
department,
> > to
> > > > > > provide joint
> > > > > > > monitoring of the patients. Dr. Pedro Marín of the
> > > hemotherapy
> > > > and
> > > > > > > hemostasis department of Hospital Clínic, together with
> Dr.
> > > > > Miquel
> > > > > > Lozano,
> > > > > > > are responsible for guiding the patients through the
> > process
> > > of
> > > > > > > cryopreservation and collection of stem cells before
the
> > > final
> > > > > > transplant.
> > > > > > >
> > > > > > > Cellular Therapy as a Strategy to Combat Crohn's
Disease
> > > > > > >
> > > > > > > Crohn's disease, together with ulcerative colitis, is
> > > included
> > > > in
> > > > > > what is
> > > > > > > called irritable bowel disease. It is a chronic genetic
> > > disease
> > > > > > that occurs
> > > > > > > when the immune system loses tolerance to the patient's
> own
> > > > > > intestinal
> > > > > > > flora, leading to an abnormal inflammatory response
that
> > > > > continues
> > > > > > over
> > > > > > > time. The results are inflammation and ulceration in
> > > different
> > > > > > areas of the
> > > > > > > digestive tract, leading to the symptoms. The disease
> > > > progresses
> > > > > in
> > > > > > the form
> > > > > > > of unpredictable and variable outbreaks throughout the
> > > > patient's
> > > > > > life and
> > > > > > > the severity of the symptoms varies according to the
> level
> > of
> > > > > > involvement of
> > > > > > > the intestines and the patient's response to the
assigned
> > > > > > treatment. It is a
> > > > > > > disease that usually affects young people between the
> ages
> > of
> > > > 18
> > > > > > and 40
> > > > > > > years, and approximately 2000 new cases are diagnosed
in
> > > Spain
> > > > > > every year.
> > > > > > > Diagnosis is often difficult because it presents
symptoms
> > > > similar
> > > > > > to those
> > > > > > > of other diseases of the digestive tract: abdominal
pain,
> > > > > diarrhea,
> > > > > > > vomiting, nausea, fever, general malaise, etc.
Patients'
> > > > quality
> > > > > of
> > > > > > life is
> > > > > > > conditioned by the severity of the disease and, in the
> most
> > > > > severe
> > > > > > cases,
> > > > > > > prevents them from leading a normal life, with a very
> high
> > > > level
> > > > > of
> > > > > > > suffering due to the acuteness and frequency of the
> > > intestinal
> > > > > > symptoms.
> > > > > > >
> > > > > > > Hospital Clínic de Barcelona is one of the few
hospitals
> in
> > > the
> > > > > > world to
> > > > > > > instate cellular therapy using autologous stem-cell
> > > > > > transplantation. In the
> > > > > > > US, the treatment has been tested on 12 patients with
> > severe
> > > > > Crohn's
> > > > > > > disease, of whom 11 have had very good results; in
Italy,
> > the
> > > > > > treatment has
> > > > > > > been applied to 4 patients, 3 of whom are also showing
> > > > excellent
> > > > > > progress
> > > > > > > following the transplant. As Hospital Clínic, 6
patients
> > with
> > > > > > Crohn's
> > > > > > > disease are already included in the process and,
> following
> > > the
> > > > > > international
> > > > > > > examples, increasing numbers of patients are expected
to
> > > choose
> > > > > > this option
> > > > > > > to treat the disease in a state that was, to date,
> > > practically
> > > > > > untreatable.
> > > > > > >
> > > > > > > In severe cases involving recurrent outbreaks
> (reactivation
> > > of
> > > > > the
> > > > > > disease
> > > > > > > several times throughout the patient's life), Crohn's
> > disease
> > > > > > presents
> > > > > > > several treatment options. Firstly, doctors choose to
use
> > > > > > corticosteroids
> > > > > > > and immunosuppressant and biological drugs to control
the
> > > > > > inflammatory
> > > > > > > process and prevent complications of the disease such
as
> > > > stenosis
> > > > > > (narrowing
> > > > > > > of the intestinal lumen) or fistulas (openings from the
> > > > > intestinal
> > > > > > lumen to
> > > > > > > other organs, such as the intestine, bladder, vagina,
or
> > > skin).
> > > > > > However,
> > > > > > > over the course of the disease, as much as 70% of
severe
> > > > patients
> > > > > > require
> > > > > > > surgery to remove segments affected by the disease, due
> to
> > > > > failure
> > > > > > of the
> > > > > > > pharmacologic approach. The surgery is occasionally
very
> > > > > aggressive
> > > > > > for the
> > > > > > > patient, as it is sometimes necessary to remove the
> entire
> > > > colon
> > > > > or
> > > > > > large
> > > > > > > sections of the small intestine, thereby considerably
> > > affecting
> > > > > the
> > > > > > > absorption of food by the intestine, with a resulting
> > > > > deterioration
> > > > > > in
> > > > > > > quality of life and body image (colostomy bag). For
this
> > > > reason,
> > > > > new
> > > > > > > treatments are being developed for patients in whom
this
> > > > solution
> > > > > > has not
> > > > > > > been an option to date.
> > > > > > >
> > > > > > > Autologous Stem-Cell Transplant: Phases of the
Procedure
> > > > > > >
> > > > > > > When the case is detected (that does not respond to
drugs
> > or
> > > > > > surgery), the
> > > > > > > patient undergoes an autologous stem-cell transplant,
> which
> > > is
> > > > a
> > > > > > bone-morrow
> > > > > > > transplant in which the immune system is reset to
prevent
> > it
> > > > from
> > > > > > attacking
> > > > > > > the intestinal flora. The process lasts approximately 2
> > > months
> > > > > and
> > > > > > consists
> > > > > > > of 6 phases:
> > > > > > >
> > > > > > > 1. Initial Chemotherapy (Cyclophosphamide + G-
CSF). In
> > > > this
> > > > > > initial
> > > > > > > phase, leukopenia or reduction of the number of
> leukocytes
> > > > > (immune-
> > > > > > system
> > > > > > > cells) in the blood is induced in the patient.
> > > > > > > 2. Migration of Stem-Cells to the Blood.
Following the
> > > > previous
> > > > > > > immunosuppression, the organism reacts by releasing
stem
> > > cells
> > > > > from
> > > > > > the bone
> > > > > > > marrow into the blood; these are the cells which will
> later
> > > be
> > > > > used
> > > > > > for the
> > > > > > > transplant.
> > > > > > > 3. Collection of Stem Cells by means of
Apheresis.
> > > > Apheresis is a
> > > > > > > technique that separates components of the blood. Here,
> the
> > > > stem
> > > > > > cells that
> > > > > > > previously migrated from the bone marrow are separated.
> > > > > > > 4. Cryopreservation of Stem Cells. When the stem
cells
> > > > have been
> > > > > > > collected by apheresis, they are frozen and preserved
> until
> > > > ready
> > > > > > for
> > > > > > > transplant.
> > > > > > > 5. Second Chemotherapy. In this phase, total
leukopenia
> > > > is
> > > > > > induced;
> > > > > > > that is, the immune system is left devoid of
leukocytes,
> > > ready
> > > > to
> > > > > > be reset
> > > > > > > with the stem-cell transplant.
> > > > > > > 6. Autologous Stem-Cell Transplant. The patient
receives
> > > > the
> > > > > > transplant
> > > > > > > by means of transfusion with his or her own stem cells.
> The
> > > > > immune
> > > > > > system is
> > > > > > > reset, leading to remission or reduction of the
abnormal
> > > > > > inflammatory
> > > > > > > process of Crohn's disease.
> > > > > > >
> > > > > >
> > > > >
> > > >
> > >
> >
>

Yes CD 133 and 34 are found there but in very small numbers.  The
largest number are found in umbilical cord stem cells.
As I said the highest concentration of MSC's is found in bone
marrow.  MSC's are also found in many other tissues as well but what
is critical is the concentraition.
There is also only one study that has shown MSC's can effect white
matter and that study was bumbed very soon after it was released for
faults in thier methods.  This was followed by another that "proved"
just the opposite which is to say that MSC's can not effect mylien.
There have also been several others that back that negitive one up.
The debate continues but as it stands now it does not appear MSC's
effect white matter.
As I said MSC's do seem to boost the other stem cells and yes this is
in part secondary to thier ability to regulate the immune response.
K

--- In stemcellsafety@yahoogroups.com, "xenovaxforever"
<thomas.ichim@...> wrote:
>
> I have to respectfully disagree.  Well it does depend on how much
> autologous adipose tissue is taken and readministered but...
>
> First of all, adipose tissue has high concentrations of mesenchymal
> stem cells, which are immune modulatory, as well as have ability to
> repair myelin.
>
> Secondly adipose tissue has high concentrations of M2 macrophages
> which are antiinflammatory
>
> Thirdly, believe it or not (i didnt at first), adipose tissue has
> both CD34 and CD133 cells ! weird !
>
> Forthly, adipose tissue has high concentrations of Treg cells
>
> below are some refernces...
>
>
> 1. Kern, S., H. Eichler, J. Stoeve, H. Kluter, and K. Bieback.
> 2006. Comparative analysis of mesenchymal stem cells from bone
> marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294-
> 1301.
> 2. Garcia-Olmo, D., M. Garcia-Arranz, D. Herreros, I. Pascual,
> C. Peiro, and J. A. Rodriguez-Montes. 2005. A phase I clinical
trial
> of the treatment of Crohn's fistula by adipose mesenchymal stem
cell
> transplantation. Dis Colon Rectum 48:1416-1423.
> 3. Stillaert, F. B., C. Di Bartolo, J. A. Hunt, N. P. Rhodes, E.
> Tognana, S. Monstrey, and P. N. Blondeel. 2008. Human clinical
> experience with adipose precursor cells seeded on hyaluronic acid-
> based spongy scaffolds. Biomaterials 29:3953-3959.
> 4. Garcia-Olmo, D., M. Garcia-Arranz, and D. Herreros. 2008.
> Expanded adipose-derived stem cells for the treatment of complex
> perianal fistula including Crohn's disease. Expert Opin Biol Ther
> 8:1417-1423.
> 5. Fang, B., Y. P. Song, L. M. Liao, Q. Han, and R. C. Zhao.
> 2006. Treatment of severe therapy-resistant acute graft-versus-host
> disease with human adipose tissue-derived mesenchymal stem cells.
> Bone Marrow Transplant 38:389-390.
> 6. Fang, B., Y. Song, R. C. Zhao, Q. Han, and Q. Lin. 2007.
> Using human adipose tissue-derived mesenchymal stem cells as
salvage
> therapy for hepatic graft-versus-host disease resembling acute
> hepatitis. Transplant Proc 39:1710-1713.
> 7. Fang, B., Y. Song, L. Liao, Y. Zhang, and R. C. Zhao. 2007.
> Favorable response to human adipose tissue-derived mesenchymal stem
> cells in steroid-refractory acute graft-versus-host disease.
> Transplant Proc 39:3358-3362.
> 8. Hayashi, O., Y. Katsube, M. Hirose, H. Ohgushi, and H. Ito.
> 2008. Comparison of osteogenic ability of rat mesenchymal stem
cells
> from bone marrow, periosteum, and adipose tissue. Calcif Tissue Int
> 82:238-247.
> 9. Noel, D., D. Caton, S. Roche, C. Bony, S. Lehmann, L.
> Casteilla, C. Jorgensen, and B. Cousin. 2008. Cell specific
> differences between human adipose-derived and mesenchymal-stromal
> cells despite similar differentiation potentials. Exp Cell Res
> 314:1575-1584.
> 10. Kim, Y., H. Kim, H. Cho, Y. Bae, K. Suh, and J. Jung. 2007.
> Direct comparison of human mesenchymal stem cells derived from
> adipose tissues and bone marrow in mediating neovascularization in
> response to vascular ischemia. Cell Physiol Biochem 20:867-876.
> 11. Keyser, K. A., K. E. Beagles, and H. P. Kiem. 2007.
> Comparison of mesenchymal stem cells from different tissues to
> suppress T-cell activation. Cell Transplant 16:555-562.
> 12. www.vet-stem.com.
> 13. Black, L. L., J. Gaynor, D. Gahring, C. Adams, D. Aron, S.
> Harman, D. A. Gingerich, and R. Harman. 2007. Effect of adipose-
> derived mesenchymal stem and regenerative cells on lameness in dogs
> with chronic osteoarthritis of the coxofemoral joints: a
randomized,
> double-blinded, multicenter, controlled trial. Vet Ther 8:272-284.
> 14. Black, L. L., J. Gaynor, C. Adams, S. Dhupa, A. E. Sams, R.
> Taylor, S. Harman, D. A. Gingerich, and R. Harman. 2008. Effect of
> intraarticular injection of autologous adipose-derived mesenchymal
> stem and regenerative cells on clinical signs of chronic
> osteoarthritis of the elbow joint in dogs. Vet Ther 9:192-200.
> 15. Lin, K., Y. Matsubara, Y. Masuda, K. Togashi, T. Ohno, T.
> Tamura, Y. Toyoshima, K. Sugimachi, M. Toyoda, H. Marc, and A.
> Douglas. 2008. Characterization of adipose tissue-derived cells
> isolated with the Celution system. Cytotherapy 10:417-426.
> 16. http://www.tissuegenesis.com/TGI%201000%20Product%
> 20Brochure.pdf.
> 17. Hang-Fu, L., G. Marmolya, and D. H. Feiglin. 1995.
> Liposuction fat-fillant implant for breast augmentation and
> reconstruction. Aesthetic Plast Surg 19:427-437.
> 18. Klein, A. W. 2001. Skin filling. Collagen and other
> injectables of the skin. Dermatol Clin 19:491-508, ix.
> 19. Hollenberg, C. H., and A. Vost. 1969. Regulation of DNA
> synthesis in fat cells and stromal elements from rat adipose
tissue.
> J Clin Invest 47:2485-2498.
> 20. Gaben-Cogneville, A. M., Y. Aron, G. Idriss, T. Jahchan, J.
> Y. Pello, and E. Swierczewski. 1983. Differentiation under the
> control of insulin of rat preadipocytes in primary culture.
Isolation
> of homogeneous cellular fractions by gradient centrifugation.
Biochim
> Biophys Acta 762:437-444.
> 21. Glick, J. M., and S. J. Adelman. 1983. Established cell lines
> from rat adipose tissue that secrete lipoprotein lipase. In Vitro
> 19:421-428.
> 22. Zuk, P. A., M. Zhu, H. Mizuno, J. Huang, J. W. Futrell, A. J.
> Katz, P. Benhaim, H. P. Lorenz, and M. H. Hedrick. 2001.
Multilineage
> cells from human adipose tissue: implications for cell-based
> therapies. Tissue Eng 7:211-228.
> 23. Zuk, P. A., M. Zhu, P. Ashjian, D. A. De Ugarte, J. I. Huang,
> H. Mizuno, Z. C. Alfonso, J. K. Fraser, P. Benhaim, and M. H.
> Hedrick. 2002. Human adipose tissue is a source of multipotent stem
> cells. Mol Biol Cell 13:4279-4295.
> 24. Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der
> Zee, T. Li, B. Witzenbichler, G. Schatteman, and J. M. Isner. 1997.
> Isolation of putative progenitor endothelial cells for
angiogenesis.
> Science 275:964-967.
> 25. Rauscher, F. M., P. J. Goldschmidt-Clermont, B. H. Davis, T.
> Wang, D. Gregg, P. Ramaswami, A. M. Pippen, B. H. Annex, C. Dong,
and
> D. A. Taylor. 2003. Aging, progenitor cell exhaustion, and
> atherosclerosis. Circulation 108:457-463.
> 26. Sata, M., D. Fukuda, K. Tanaka, Y. Kaneda, H. Yashiro, and I.
> Shirakawa. 2005. The role of circulating precursors in vascular
> repair and lesion formation. J Cell Mol Med 9:557-568.
> 27. Miranville, A., C. Heeschen, C. Sengenes, C. A. Curat, R.
> Busse, and A. Bouloumie. 2004. Improvement of postnatal
> neovascularization by human adipose tissue-derived stem cells.
> Circulation 110:349-355.
> 28. Urbich, C., and S. Dimmeler. 2005. Risk factors for coronary
> artery disease, circulating endothelial progenitor cells, and the
> role of HMG-CoA reductase inhibitors. Kidney Int 67:1672-1676.
> 29. Planat-Benard, V., J. S. Silvestre, B. Cousin, M. Andre, M.
> Nibbelink, R. Tamarat, M. Clergue, C. Manneville, C. Saillan-
Barreau,
> M. Duriez, A. Tedgui, B. Levy, L. Penicaud, and L. Casteilla. 2004.
> Plasticity of human adipose lineage cells toward endothelial cells:
> physiological and therapeutic perspectives. Circulation 109:656-663.
> 30. Rehman, J., D. Traktuev, J. Li, S. Merfeld-Clauss, C. J. Temm-
> Grove, J. E. Bovenkerk, C. L. Pell, B. H. Johnstone, R. V.
Considine,
> and K. L. March. 2004. Secretion of angiogenic and antiapoptotic
> factors by human adipose stromal cells. Circulation 109:1292-1298.
> 31. Cai, L., B. H. Johnstone, T. G. Cook, Z. Liang, D. Traktuev,
> K. Cornetta, D. A. Ingram, E. D. Rosen, and K. L. March. 2007.
> Suppression of hepatocyte growth factor production impairs the
> ability of adipose-derived stem cells to promote ischemic tissue
> revascularization. Stem Cells 25:3234-3243.
> 32. Sumi, M., M. Sata, N. Toya, K. Yanaga, T. Ohki, and R. Nagai.
> 2007. Transplantation of adipose stromal cells, but not mature
> adipocytes, augments ischemia-induced angiogenesis. Life Sci 80:559-
> 565.
> 33. Minana, M. D., F. Carbonell-Uberos, V. Mirabet, S. Marin, and
> A. Encabo. 2008. IFATS collection: Identification of hemangioblasts
> in the adult human adipose tissue. Stem Cells 26:2696-2704.
> 34. Astori, G., F. Vignati, S. Bardelli, M. Tubio, M. Gola, V.
> Albertini, F. Bambi, G. Scali, D. Castelli, V. Rasini, G. Soldati,
> and T. Moccetti. 2007. "In vitro" and multicolor phenotypic
> characterization of cell subpopulations identified in fresh human
> adipose tissue stromal vascular fraction and in the derived
> mesenchymal stem cells. J Transl Med 5:55.
> 35. Varma, M. J., R. G. Breuls, T. E. Schouten, W. J. Jurgens, H.
> J. Bontkes, G. J. Schuurhuis, S. M. van Ham, and F. J. van
Milligen.
> 2007. Phenotypical and functional characterization of freshly
> isolated adipose tissue-derived stem cells. Stem Cells Dev 16:91-
104.
> 36. Ruhnke, M., H. Ungefroren, A. Nussler, F. Martin, M.
> Brulport, W. Schormann, J. G. Hengstler, W. Klapper, K. Ulrichs, J.
> A. Hutchinson, B. Soria, R. M. Parwaresch, P. Heeckt, B. Kremer,
and
> F. Fandrich. 2005. Differentiation of in vitro-modified human
> peripheral blood monocytes into hepatocyte-like and pancreatic
islet-
> like cells. Gastroenterology 128:1774-1786.
> 37. Ruhnke, M., A. K. Nussler, H. Ungefroren, J. G. Hengstler, B.
> Kremer, W. Hoeckh, T. Gottwald, P. Heeckt, and F. Fandrich. 2005.
> Human monocyte-derived neohepatocytes: a promising alternative to
> primary human hepatocytes for autologous cell therapy.
> Transplantation 79:1097-1103.
> 38. Suganami, T., J. Nishida, and Y. Ogawa. 2005. A paracrine
> loop between adipocytes and macrophages aggravates inflammatory
> changes: role of free fatty acids and tumor necrosis factor alpha.
> Arterioscler Thromb Vasc Biol 25:2062-2068.
> 39. Bastard, J. P., M. Maachi, C. Lagathu, M. J. Kim, M. Caron,
> H. Vidal, J. Capeau, and B. Feve. 2006. Recent advances in the
> relationship between obesity, inflammation, and insulin resistance.
> Eur Cytokine Netw 17:4-12.
> 40. Zeyda, M., and T. M. Stulnig. 2007. Adipose tissue
> macrophages. Immunol Lett 112:61-67.
> 41. Odegaard, J. I., R. R. Ricardo-Gonzalez, M. H. Goforth, C. R.
> Morel, V. Subramanian, L. Mukundan, A. R. Eagle, D. Vats, F.
> Brombacher, A. W. Ferrante, and A. Chawla. 2007. Macrophage-
specific
> PPARgamma controls alternative activation and improves insulin
> resistance. Nature 447:1116-1120.
> 42. Zeyda, M., D. Farmer, J. Todoric, O. Aszmann, M. Speiser, G.
> Gyori, G. J. Zlabinger, and T. M. Stulnig. 2007. Human adipose
tissue
> macrophages are of an anti-inflammatory phenotype but capable of
> excessive pro-inflammatory mediator production. Int J Obes (Lond)
> 31:1420-1428.
> 43. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A.
> Sica. 2002. Macrophage polarization: tumor-associated macrophages
as
> a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol
> 23:549-555.
> 44. Mehta, A., R. Brewington, M. Chatterji, M. Zoubine, G. T.
> Kinasewitz, G. T. Peer, A. C. Chang, F. B. Taylor, Jr., and A.
> Shnyra. 2004. Infection-induced modulation of m1 and m2 phenotypes
in
> circulating monocytes: role in immune monitoring and early
prognosis
> of sepsis. Shock 22:423-430.
> 45. Song, G. Y., C. S. Chung, D. Jarrar, I. H. Chaudry, and A.
> Ayala. 2001. Evolution of an immune suppressive macrophage
phenotype
> as a product of P38 MAPK activation in polymicrobial sepsis. Shock
> 15:42-48.
> 46. Gustafsson, C., J. Mjosberg, A. Matussek, R. Geffers, L.
> Matthiesen, G. Berg, S. Sharma, J. Buer, and J. Ernerudh. 2008.
Gene
> expression profiling of human decidual macrophages: evidence for
> immunosuppressive phenotype. PLoS ONE 3:e2078.
> 47. Wang, Y., Y. P. Wang, G. Zheng, V. W. Lee, L. Ouyang, D. H.
> Chang, D. Mahajan, J. Coombs, Y. M. Wang, S. I. Alexander, and D.
C.
> Harris. 2007. Ex vivo programmed macrophages ameliorate
experimental
> chronic inflammatory renal disease. Kidney Int 72:290-299.
> 48. Ponomarev, E. D., K. Maresz, Y. Tan, and B. N. Dittel. 2007.
> CNS-derived interleukin-4 is essential for the regulation of
> autoimmune inflammation and induces a state of alternative
activation
> in microglial cells. J Neurosci 27:10714-10721.
> 49. Zhang, X., M. Li, D. Lian, X. Zheng, Z. X. Zhang, T. E.
> Ichim, X. Xia, X. Huang, C. Vladau, M. Suzuki, B. Garcia, A. M.
> Jevnikar, and W. P. Min. 2008. Generation of therapeutic dendritic
> cells and regulatory T cells for preventing allogeneic cardiac
graft
> rejection. Clin Immunol 127:313-321.
> 50. Ichim, T. E., R. Zhong, and W. P. Min. 2003. Prevention of
> allograft rejection by in vitro generated tolerogenic dendritic
> cells. Transpl Immunol 11:295-306.
> 51. Tiemessen, M. M., A. L. Jagger, H. G. Evans, M. J. van
> Herwijnen, S. John, and L. S. Taams. 2007. CD4+CD25+Foxp3+
regulatory
> T cells induce alternative activation of human
monocytes/macrophages.
> Proc Natl Acad Sci U S A 104:19446-19451.
> 52. Ryan, J. M., F. Barry, J. M. Murphy, and B. P. Mahon. 2007.
> Interferon-gamma does not break, but promotes the immunosuppressive
> capacity of adult human mesenchymal stem cells. Clin Exp Immunol
> 149:353-363.
> 53. Ye, Z., Y. Wang, H. Y. Xie, and S. S. Zheng. 2008.
> Immunosuppressive effects of rat mesenchymal stem cells:
involvement
> of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int
7:608-
> 614.
> 54. Askenasy, N., A. Kaminitz, and S. Yarkoni. 2008. Mechanisms
> of T regulatory cell function. Autoimmun Rev 7:370-375.
> 55. Gonzalez-Rey, E., M. A. Gonzalez, N. Varela, F. O'Valle, P.
> Hernandez-Cortes, L. Rico, D. Buscher, and M. Delgado. 2009. Human
> adipose-derived mesenchymal stem cells reduce inflammatory and T-
cell
> responses and induce regulatory T cells in vitro in rheumatoid
> arthritis. Ann Rheum Dis.
> 56. Casiraghi, F., N. Azzollini, P. Cassis, B. Imberti, M.
> Morigi, D. Cugini, R. A. Cavinato, M. Todeschini, S. Solini, A.
> Sonzogni, N. Perico, G. Remuzzi, and M. Noris. 2008. Pretransplant
> infusion of mesenchymal stem cells prolongs the survival of a
> semiallogeneic heart transplant through the generation of
regulatory
> T cells. J Immunol 181:3933-3946.
> 57. Di Ianni, M., B. Del Papa, M. De Ioanni, L. Moretti, E.
> Bonifacio, D. Cecchini, P. Sportoletti, F. Falzetti, and A.
Tabilio.
> 2008. Mesenchymal cells recruit and regulate T regulatory cells.
Exp
> Hematol 36:309-318.
> 58. Zannettino, A. C., S. Paton, A. Arthur, F. Khor, S. Itescu,
> J. M. Gimble, and S. Gronthos. 2008. Multipotential human adipose-
> derived stromal stem cells exhibit a perivascular phenotype in
vitro
> and in vivo. J Cell Physiol 214:413-421.
> 59. Hoogduijn, M. J., M. J. Crop, A. M. Peeters, G. J. Van Osch,
> A. H. Balk, J. N. Ijzermans, W. Weimar, and C. C. Baan. 2007. Human
> heart, spleen, and perirenal fat-derived mesenchymal stem cells
have
> immunomodulatory capacities. Stem Cells Dev 16:597-604.
> 60. Chao, K. C., K. F. Chao, Y. S. Fu, and S. H. Liu. 2008. Islet-
> like clusters derived from mesenchymal stem cells in Wharton's
Jelly
> of the human umbilical cord for transplantation to control type 1
> diabetes. PLoS ONE 3:e1451.
> 61. Jo, Y. Y., H. J. Lee, S. Y. Kook, H. W. Choung, J. Y. Park,
> J. H. Chung, Y. H. Choung, E. S. Kim, H. C. Yang, and P. H. Choung.
> 2007. Isolation and characterization of postnatal stem cells from
> human dental tissues. Tissue Eng 13:767-773.
> 62. He, Q., C. Wan, and G. Li. 2007. Concise review: multipotent
> mesenchymal stromal cells in blood. Stem Cells 25:69-77.
> 63. Djouad, F., L. M. Charbonnier, C. Bouffi, P. Louis-Plence, C.
> Bony, F. Apparailly, C. Cantos, C. Jorgensen, and D. Noel. 2007.
> Mesenchymal stem cells inhibit the differentiation of dendritic
cells
> through an interleukin-6-dependent mechanism. Stem Cells 25:2025-
2032.
> 64. English, K., F. P. Barry, and B. P. Mahon. 2008. Murine
> mesenchymal stem cells suppress dendritic cell migration,
maturation
> and antigen presentation. Immunol Lett 115:50-58.
> 65. Nemeth, K., A. Leelahavanichkul, P. S. Yuen, B. Mayer, A.
> Parmelee, K. Doi, P. G. Robey, K. Leelahavanichkul, B. H. Koller,
J.
> M. Brown, X. Hu, I. Jelinek, R. A. Star, and E. Mezey. 2009. Bone
> marrow stromal cells attenuate sepsis via prostaglandin E(2)-
> dependent reprogramming of host macrophages to increase their
> interleukin-10 production. Nat Med 15:42-49.
> 66. Ortiz, L. A., M. Dutreil, C. Fattman, A. C. Pandey, G.
> Torres, K. Go, and D. G. Phinney. 2007. Interleukin 1 receptor
> antagonist mediates the antiinflammatory and antifibrotic effect of
> mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A
> 104:11002-11007.
> 67. Nasef, A., A. Chapel, C. Mazurier, S. Bouchet, M. Lopez, N.
> Mathieu, L. Sensebe, Y. Zhang, N. C. Gorin, D. Thierry, and L.
> Fouillard. 2007. Identification of IL-10 and TGF-beta transcripts
> involved in the inhibition of T-lymphocyte proliferation during
cell
> contact with human mesenchymal stem cells. Gene Expr 13:217-226.
> 68. Karussis, D., and I. Kassis. 2008. The potential use of stem
> cells in multiple sclerosis: an overview of the preclinical
> experience. Clin Neurol Neurosurg 110:889-896.
> 69. Zappia, E., S. Casazza, E. Pedemonte, F. Benvenuto, I.
> Bonanni, E. Gerdoni, D. Giunti, A. Ceravolo, F. Cazzanti, F.
> Frassoni, G. Mancardi, and A. Uccelli. 2005. Mesenchymal stem cells
> ameliorate experimental autoimmune encephalomyelitis inducing T-
cell
> anergy. Blood 106:1755-1761.
> 70. Boumaza, I., S. Srinivasan, W. T. Witt, C. Feghali-Bostwick,
> Y. Dai, A. Garcia-Ocana, and M. Feili-Hariri. 2008. Autologous bone
> marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin
> expression in the islets, alter T cell cytokine pattern and
preserve
> regulatory T cells in the periphery and induce sustained
> normoglycemia. J Autoimmun.
> 71. Zhou, K., H. Zhang, O. Jin, X. Feng, G. Yao, Y. Hou, and L.
> Sun. 2008. Transplantation of human bone marrow mesenchymal stem
cell
> ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol
> Immunol 5:417-424.
> 72. Parekkadan, B., A. W. Tilles, and M. L. Yarmush. 2008. Bone
> marrow-derived mesenchymal stem cells ameliorate autoimmune
> enteropathy independently of regulatory T cells. Stem Cells 26:1913-
> 1919.
> 73. Arthur, A., A. Zannettino, and S. Gronthos. 2009. The
> therapeutic applications of multipotential mesenchymal/stromal stem
> cells in skeletal tissue repair. J Cell Physiol 218:237-245.
> 74. Mishra, P. K. 2008. Bone marrow-derived mesenchymal stem
> cells for treatment of heart failure: is it all paracrine actions
and
> immunomodulation? J Cardiovasc Med (Hagerstown) 9:122-128.
> 75. Centeno, C. J., D. Busse, J. Kisiday, C. Keohan, M. Freeman,
> and D. Karli. 2008. Increased knee cartilage volume in degenerative
> joint disease using percutaneously implanted, autologous
mesenchymal
> stem cells. Pain Physician 11:343-353.
> 76. Katritsis, D. 2008. Cellular replacement therapy for
> arrhythmia treatment: early clinical experience. J Interv Card
> Electrophysiol 22:99-105.
> 77. Slavin, S., B. G. Kurkalli, and D. Karussis. 2008. The
> potential use of adult stem cells for the treatment of multiple
> sclerosis and other neurodegenerative disorders. Clin Neurol
> Neurosurg 110:943-946.
> 78. Rosati, G. 2001. The prevalence of multiple sclerosis in the
> world: an update. Neurol Sci 22:117-139.
> 79. Pittock, S. J., and C. F. Lucchinetti. 2007. The pathology of
> MS: new insights and potential clinical applications. Neurologist
> 13:45-56.
> 80. Saresella, M., I. Marventano, R. Longhi, F. Lissoni, D.
> Trabattoni, L. Mendozzi, D. Caputo, and M. Clerici. 2008.
> CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable
relapsing-
> remitting multiple sclerosis and their modulation by therapy. FASEB
J
> 22:3500-3508.
> 81. Korporal, M., J. Haas, B. Balint, B. Fritzsching, A. Schwarz,
> S. Moeller, B. Fritz, E. Suri-Payer, and B. Wildemann. 2008.
> Interferon beta-induced restoration of regulatory T-cell function
in
> multiple sclerosis is prompted by an increase in newly generated
> naive regulatory T cells. Arch Neurol 65:1434-1439.
> 82. Akirav, E. M., C. M. Bergman, M. Hill, and N. H. Ruddle.
> 2009. Depletion of CD4(+)CD25(+) T cells exacerbates experimental
> autoimmune encephalomyelitis induced by mouse, but not rat,
antigens.
> J Neurosci Res.
> 83. Reddy, J., Z. Illes, X. Zhang, J. Encinas, J. Pyrdol, L.
> Nicholson, R. A. Sobel, K. W. Wucherpfennig, and V. K. Kuchroo.
2004.
> Myelin proteolipid protein-specific CD4+CD25+ regulatory cells
> mediate genetic resistance to experimental autoimmune
> encephalomyelitis. Proc Natl Acad Sci U S A 101:15434-15439.
> 84. Gregg, C., V. Shikar, P. Larsen, G. Mak, A. Chojnacki, V. W.
> Yong, and S. Weiss. 2007. White matter plasticity and enhanced
> remyelination in the maternal CNS. J Neurosci 27:1812-1823.
> 85. Penner, I. K., L. Kappos, M. Rausch, K. Opwis, and E. W.
> Radu. 2006. Therapy-induced plasticity of cognitive functions in MS
> patients: insights from fMRI. J Physiol Paris 99:455-462.
> 86. Nait-Oumesmar, B., N. Picard-Riera, C. Kerninon, L. Decker,
> D. Seilhean, G. U. Hoglinger, E. C. Hirsch, R. Reynolds, and A.
Baron-
> Van Evercooren. 2007. Activation of the subventricular zone in
> multiple sclerosis: evidence for early glial progenitors. Proc Natl
> Acad Sci U S A 104:4694-4699.
> 87. Kassis, I., N. Grigoriadis, B. Gowda-Kurkalli, R. Mizrachi-
> Kol, T. Ben-Hur, S. Slavin, O. Abramsky, and D. Karussis. 2008.
> Neuroprotection and immunomodulation with mesenchymal stem cells in
> chronic experimental autoimmune encephalomyelitis. Arch Neurol
65:753-
> 761.
> 88. Bai, L., D. P. Lennon, V. Eaton, K. Maier, A. I. Caplan, S.
> D. Miller, and R. H. Miller. 2009. Human bone marrow-derived
> mesenchymal stem cells induce Th2-polarized immune response and
> promote endogenous repair in animal models of multiple sclerosis.
> Glia.
> 89. Mohyeddin Bonab, M., S. Yazdanbakhsh, J. Lotfi, K.
> Alimoghaddom, F. Talebian, F. Hooshmand, A. Ghavamzadeh, and B.
> Nikbin. 2007. Does mesenchymal stem cell therapy help multiple
> sclerosis patients? Report of a pilot study. Iran J Immunol 4:50-57.
> 90. Martino, G., R. Furlan, E. Brambilla, A. Bergami, F. Ruffini,
> M. Gironi, P. L. Poliani, L. M. Grimaldi, and G. Comi. 2000.
> Cytokines and immunity in multiple sclerosis: the dual signal
> hypothesis. J Neuroimmunol 109:3-9.
> 91. Hafler, D. A., J. M. Slavik, D. E. Anderson, K. C. O'Connor,
> P. De Jager, and C. Baecher-Allan. 2005. Multiple sclerosis.
Immunol
> Rev 204:208-231.
> 92. Viglietta, V., C. Baecher-Allan, H. L. Weiner, and D. A.
> Hafler. 2004. Loss of functional suppression by CD4+CD25+
regulatory
> T cells in patients with multiple sclerosis. J Exp Med 199:971-979.
> 93. Kornek, B., and H. Lassmann. 2003. Neuropathology of multiple
> sclerosis-new concepts. Brain Res Bull 61:321-326.
> 94. Kornek, B., M. K. Storch, R. Weissert, E. Wallstroem, A.
> Stefferl, T. Olsson, C. Linington, M. Schmidbauer, and H. Lassmann.
> 2000. Multiple sclerosis and chronic autoimmune encephalomyelitis:
a
> comparative quantitative study of axonal injury in active,
inactive,
> and remyelinated lesions. Am J Pathol 157:267-276.
>
>
>
>
>
> --- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@> wrote:
> >
> > I was referring to stem cells taken from Adipose tissue which is
> > being used to treat many diagnosis'.  I use the word "treat"
> lightly.
> > Do you remember a few years ago when it all began...shark stem
> cells
> > being given to humans for an array of issues.  Then came the pigs.
> > There is no evidence to lead one to think adipose stem cells will
> > improve any disorder much less one as complex as MS which
involves
> > the brain and the entire nervous system of the body.  What MS
> > patients need are partcular subset of stem cells namely CD1333
and
> > CD34.  For best results boost these with MSC's which are found in
> the
> > highest concentraition in the bone marrow.
> > K
> >
> > --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> > <thomas.ichim@> wrote:
> > >
> > > Are you talking about autologous fat for crohn's being a "fad"?
> > >
> > > or about Costa Rica?
> > >
> > >
> > >
> > > --- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@>
> wrote:
> > > >
> > > > There are "fads" even in the stem cell world and this is an
> > example
> > > > of yet another treatment designed to line the pockets.  This
> > > > treatment was created a couple of years ago but not much has
> been
> > > > reported about it because it has shown so little promise.
> > > > Buyer beware.
> > > >
> > > > --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> > > > <thomas.ichim@> wrote:
> > > > >
> > > > > did you guys see they also are doing autologous fat for MS
in
> > > Costa
> > > > > Rica?
> > > > >
> > > > > http://www.youtube.com/watch?v=k3Z1J3QmYoE
> > > > >
> > > > >
> > > > >
> > > > > --- In stemcellsafety@yahoogroups.com, "Kirshner Ross-
Vaden"
> > > > > <kirsh@> wrote:
> > > > > >
> > > > > >
> > > > > > Stem Cell Treatment For Crohn's Disease
> > > > > >
> > > > > >
> > > > > > Article Date: 21 Feb 2009 - 0:00 PST
> > > > > >
> > > > > >
> > > > > >
> > > > > >   _____
> > > > > >
> > > > > >
> > > > > > Cellular therapy with stem cells
> > > > > >
> > > > >
> > > >
> > >
> >
>
<http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>
> > > > >  is
> > > > > > revolutionizing the focus of treatment of many serious
> > > diseases.
> > > > > Replacing
> > > > > > the cells of damaged tissue with other new cells from the
> > same
> > > > > patient is
> > > > > > already a reality. This is the basis of cellular therapy
> and
> > > > > regenerative
> > > > > > medicine, the latest great advance in biomedicine. In
this
> > > line,
> > > > > Hospital
> > > > > > Clínic, Barcelona is leading the world in the application
> of
> > an
> > > > > innovative
> > > > > > cellular therapy that uses stem cells to treat Crohn's
> > disease,
> > > a
> > > > > chronic
> > > > > > genetic disease that affects 1% of the population in
Spain
> > and
> > > > > which has
> > > > > > considerable impact on the quality of life of the
patients.
> > The
> > > > > procedure is
> > > > > > based on an autologous bone-marrow transplant (when
> patients
> > > > > receive a
> > > > > > transplant of their own stem cells) and now constitutes a
> > > > treatment
> > > > > option
> > > > > > to cure an intestinal disease that sometimes does not
> > > > successfully
> > > > > respond
> > > > > > to drugs and requires highly complex surgery that does
not
> > > > provide
> > > > > a cure.
> > > > > >
> > > > > > Hospital Clínic, Barcelona is one of the few hospitals in
> the
> > > > world
> > > > > to apply
> > > > > > this new therapeutic option for patients with Crohn's
> > disease,
> > > > and
> > > > > it does
> > > > > > so with the guarantee of success experienced in the US
and
> > > Italy,
> > > > > where the
> > > > > > technique has been tested with excellent results: in an
> > average
> > > > > follow-up
> > > > > > period of 6 years, 80% of transplant patients are in a
> phase
> > of
> > > > > total
> > > > > > remission of the disease and the remaining 20% have shown
> > > > > considerable
> > > > > > improvement following the transplant, and are now
> responding
> > > > > favorably to
> > > > > > drugs. Dr. Julián Panés and Dr. Elena Ricart over the
> > > > > Gastroenterology
> > > > > > Department of Hospital Clínic, Barcelona are the driving
> > force
> > > > > behind this
> > > > > > therapy in Spain and began to implement regenerative
> cellular
> > > > > therapy in
> > > > > > patients with Crohn's disease in August 2008. To date, a
> > total
> > > of
> > > > 6
> > > > > patients
> > > > > > are benefiting from this new treatment, of whom 3 I've
> > already
> > > > > completed the
> > > > > > process and are in the follow-up face, and a further 3
are
> at
> > > > > different
> > > > > > stages of therapy. The transplant requires several weeks
of
> > > > > admission to
> > > > > > hospital before patients receive their own cells.
> > > > > >
> > > > > > The success of autologous stem-cell transplants in
Crohn's
> > > > disease
> > > > > is
> > > > > > possible thanks to the joint collaboration of the
> > > > gastroenterology
> > > > > and
> > > > > > hematology departments and of the hemotherapy and
> hemostasis
> > > > > department, as
> > > > > > the procedure is the same as that carried out in bone-
> morrow
> > > > > transplants to
> > > > > > cure leukemia or myeloma. Thus, when a case is detected,
> the
> > > > > professionals
> > > > > > from the different departments of Hospital Clinic,
> Barcelona
> > > > > supervise each
> > > > > > of the phases of the process to autologous Transplant. In
> > this
> > > > > case, Dr.
> > > > > > Panés and Dr. Ricart from the gastroenterology department
> > work
> > > > > together with
> > > > > > Dr. Montserrat Rovira from the hematology department of
the
> > > > Catalan
> > > > > hospital
> > > > > > and with Dr. Enric Carreras, the head of this department,
> to
> > > > > provide joint
> > > > > > monitoring of the patients. Dr. Pedro Marín of the
> > hemotherapy
> > > and
> > > > > > hemostasis department of Hospital Clínic, together with
Dr.
> > > > Miquel
> > > > > Lozano,
> > > > > > are responsible for guiding the patients through the
> process
> > of
> > > > > > cryopreservation and collection of stem cells before the
> > final
> > > > > transplant.
> > > > > >
> > > > > > Cellular Therapy as a Strategy to Combat Crohn's Disease
> > > > > >
> > > > > > Crohn's disease, together with ulcerative colitis, is
> > included
> > > in
> > > > > what is
> > > > > > called irritable bowel disease. It is a chronic genetic
> > disease
> > > > > that occurs
> > > > > > when the immune system loses tolerance to the patient's
own
> > > > > intestinal
> > > > > > flora, leading to an abnormal inflammatory response that
> > > > continues
> > > > > over
> > > > > > time. The results are inflammation and ulceration in
> > different
> > > > > areas of the
> > > > > > digestive tract, leading to the symptoms. The disease
> > > progresses
> > > > in
> > > > > the form
> > > > > > of unpredictable and variable outbreaks throughout the
> > > patient's
> > > > > life and
> > > > > > the severity of the symptoms varies according to the
level
> of
> > > > > involvement of
> > > > > > the intestines and the patient's response to the assigned
> > > > > treatment. It is a
> > > > > > disease that usually affects young people between the
ages
> of
> > > 18
> > > > > and 40
> > > > > > years, and approximately 2000 new cases are diagnosed in
> > Spain
> > > > > every year.
> > > > > > Diagnosis is often difficult because it presents symptoms
> > > similar
> > > > > to those
> > > > > > of other diseases of the digestive tract: abdominal pain,
> > > > diarrhea,
> > > > > > vomiting, nausea, fever, general malaise, etc. Patients'
> > > quality
> > > > of
> > > > > life is
> > > > > > conditioned by the severity of the disease and, in the
most
> > > > severe
> > > > > cases,
> > > > > > prevents them from leading a normal life, with a very
high
> > > level
> > > > of
> > > > > > suffering due to the acuteness and frequency of the
> > intestinal
> > > > > symptoms.
> > > > > >
> > > > > > Hospital Clínic de Barcelona is one of the few hospitals
in
> > the
> > > > > world to
> > > > > > instate cellular therapy using autologous stem-cell
> > > > > transplantation. In the
> > > > > > US, the treatment has been tested on 12 patients with
> severe
> > > > Crohn's
> > > > > > disease, of whom 11 have had very good results; in Italy,
> the
> > > > > treatment has
> > > > > > been applied to 4 patients, 3 of whom are also showing
> > > excellent
> > > > > progress
> > > > > > following the transplant. As Hospital Clínic, 6 patients
> with
> > > > > Crohn's
> > > > > > disease are already included in the process and,
following
> > the
> > > > > international
> > > > > > examples, increasing numbers of patients are expected to
> > choose
> > > > > this option
> > > > > > to treat the disease in a state that was, to date,
> > practically
> > > > > untreatable.
> > > > > >
> > > > > > In severe cases involving recurrent outbreaks
(reactivation
> > of
> > > > the
> > > > > disease
> > > > > > several times throughout the patient's life), Crohn's
> disease
> > > > > presents
> > > > > > several treatment options. Firstly, doctors choose to use
> > > > > corticosteroids
> > > > > > and immunosuppressant and biological drugs to control the
> > > > > inflammatory
> > > > > > process and prevent complications of the disease such as
> > > stenosis
> > > > > (narrowing
> > > > > > of the intestinal lumen) or fistulas (openings from the
> > > > intestinal
> > > > > lumen to
> > > > > > other organs, such as the intestine, bladder, vagina, or
> > skin).
> > > > > However,
> > > > > > over the course of the disease, as much as 70% of severe
> > > patients
> > > > > require
> > > > > > surgery to remove segments affected by the disease, due
to
> > > > failure
> > > > > of the
> > > > > > pharmacologic approach. The surgery is occasionally very
> > > > aggressive
> > > > > for the
> > > > > > patient, as it is sometimes necessary to remove the
entire
> > > colon
> > > > or
> > > > > large
> > > > > > sections of the small intestine, thereby considerably
> > affecting
> > > > the
> > > > > > absorption of food by the intestine, with a resulting
> > > > deterioration
> > > > > in
> > > > > > quality of life and body image (colostomy bag). For this
> > > reason,
> > > > new
> > > > > > treatments are being developed for patients in whom this
> > > solution
> > > > > has not
> > > > > > been an option to date.
> > > > > >
> > > > > > Autologous Stem-Cell Transplant: Phases of the Procedure
> > > > > >
> > > > > > When the case is detected (that does not respond to drugs
> or
> > > > > surgery), the
> > > > > > patient undergoes an autologous stem-cell transplant,
which
> > is
> > > a
> > > > > bone-morrow
> > > > > > transplant in which the immune system is reset to prevent
> it
> > > from
> > > > > attacking
> > > > > > the intestinal flora. The process lasts approximately 2
> > months
> > > > and
> > > > > consists
> > > > > > of 6 phases:
> > > > > >
> > > > > > 1. Initial Chemotherapy (Cyclophosphamide + G-CSF). In
> > > this
> > > > > initial
> > > > > > phase, leukopenia or reduction of the number of
leukocytes
> > > > (immune-
> > > > > system
> > > > > > cells) in the blood is induced in the patient.
> > > > > > 2. Migration of Stem-Cells to the Blood. Following the
> > > previous
> > > > > > immunosuppression, the organism reacts by releasing stem
> > cells
> > > > from
> > > > > the bone
> > > > > > marrow into the blood; these are the cells which will
later
> > be
> > > > used
> > > > > for the
> > > > > > transplant.
> > > > > > 3. Collection of Stem Cells by means of Apheresis.
> > > Apheresis is a
> > > > > > technique that separates components of the blood. Here,
the
> > > stem
> > > > > cells that
> > > > > > previously migrated from the bone marrow are separated.
> > > > > > 4. Cryopreservation of Stem Cells. When the stem cells
> > > have been
> > > > > > collected by apheresis, they are frozen and preserved
until
> > > ready
> > > > > for
> > > > > > transplant.
> > > > > > 5. Second Chemotherapy. In this phase, total leukopenia
> > > is
> > > > > induced;
> > > > > > that is, the immune system is left devoid of leukocytes,
> > ready
> > > to
> > > > > be reset
> > > > > > with the stem-cell transplant.
> > > > > > 6. Autologous Stem-Cell Transplant. The patient receives
> > > the
> > > > > transplant
> > > > > > by means of transfusion with his or her own stem cells.
The
> > > > immune
> > > > > system is
> > > > > > reset, leading to remission or reduction of the abnormal
> > > > > inflammatory
> > > > > > process of Crohn's disease.
> > > > > >
> > > > >
> > > >
> > >
> >
>

I have to respectfully disagree.  Well it does depend on how much
autologous adipose tissue is taken and readministered but...

First of all, adipose tissue has high concentrations of mesenchymal
stem cells, which are immune modulatory, as well as have ability to
repair myelin.

Secondly adipose tissue has high concentrations of M2 macrophages
which are antiinflammatory

Thirdly, believe it or not (i didnt at first), adipose tissue has
both CD34 and CD133 cells ! weird !

Forthly, adipose tissue has high concentrations of Treg cells

below are some refernces...


1. Kern, S., H. Eichler, J. Stoeve, H. Kluter, and K. Bieback.
2006. Comparative analysis of mesenchymal stem cells from bone
marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294-
1301.
2. Garcia-Olmo, D., M. Garcia-Arranz, D. Herreros, I. Pascual,
C. Peiro, and J. A. Rodriguez-Montes. 2005. A phase I clinical trial
of the treatment of Crohn's fistula by adipose mesenchymal stem cell
transplantation. Dis Colon Rectum 48:1416-1423.
3. Stillaert, F. B., C. Di Bartolo, J. A. Hunt, N. P. Rhodes, E.
Tognana, S. Monstrey, and P. N. Blondeel. 2008. Human clinical
experience with adipose precursor cells seeded on hyaluronic acid-
based spongy scaffolds. Biomaterials 29:3953-3959.
4. Garcia-Olmo, D., M. Garcia-Arranz, and D. Herreros. 2008.
Expanded adipose-derived stem cells for the treatment of complex
perianal fistula including Crohn's disease. Expert Opin Biol Ther
8:1417-1423.
5. Fang, B., Y. P. Song, L. M. Liao, Q. Han, and R. C. Zhao.
2006. Treatment of severe therapy-resistant acute graft-versus-host
disease with human adipose tissue-derived mesenchymal stem cells.
Bone Marrow Transplant 38:389-390.
6. Fang, B., Y. Song, R. C. Zhao, Q. Han, and Q. Lin. 2007.
Using human adipose tissue-derived mesenchymal stem cells as salvage
therapy for hepatic graft-versus-host disease resembling acute
hepatitis. Transplant Proc 39:1710-1713.
7. Fang, B., Y. Song, L. Liao, Y. Zhang, and R. C. Zhao. 2007.
Favorable response to human adipose tissue-derived mesenchymal stem
cells in steroid-refractory acute graft-versus-host disease.
Transplant Proc 39:3358-3362.
8. Hayashi, O., Y. Katsube, M. Hirose, H. Ohgushi, and H. Ito.
2008. Comparison of osteogenic ability of rat mesenchymal stem cells
from bone marrow, periosteum, and adipose tissue. Calcif Tissue Int
82:238-247.
9. Noel, D., D. Caton, S. Roche, C. Bony, S. Lehmann, L.
Casteilla, C. Jorgensen, and B. Cousin. 2008. Cell specific
differences between human adipose-derived and mesenchymal-stromal
cells despite similar differentiation potentials. Exp Cell Res
314:1575-1584.
10. Kim, Y., H. Kim, H. Cho, Y. Bae, K. Suh, and J. Jung. 2007.
Direct comparison of human mesenchymal stem cells derived from
adipose tissues and bone marrow in mediating neovascularization in
response to vascular ischemia. Cell Physiol Biochem 20:867-876.
11. Keyser, K. A., K. E. Beagles, and H. P. Kiem. 2007.
Comparison of mesenchymal stem cells from different tissues to
suppress T-cell activation. Cell Transplant 16:555-562.
12. www.vet-stem.com.
13. Black, L. L., J. Gaynor, D. Gahring, C. Adams, D. Aron, S.
Harman, D. A. Gingerich, and R. Harman. 2007. Effect of adipose-
derived mesenchymal stem and regenerative cells on lameness in dogs
with chronic osteoarthritis of the coxofemoral joints: a randomized,
double-blinded, multicenter, controlled trial. Vet Ther 8:272-284.
14. Black, L. L., J. Gaynor, C. Adams, S. Dhupa, A. E. Sams, R.
Taylor, S. Harman, D. A. Gingerich, and R. Harman. 2008. Effect of
intraarticular injection of autologous adipose-derived mesenchymal
stem and regenerative cells on clinical signs of chronic
osteoarthritis of the elbow joint in dogs. Vet Ther 9:192-200.
15. Lin, K., Y. Matsubara, Y. Masuda, K. Togashi, T. Ohno, T.
Tamura, Y. Toyoshima, K. Sugimachi, M. Toyoda, H. Marc, and A.
Douglas. 2008. Characterization of adipose tissue-derived cells
isolated with the Celution system. Cytotherapy 10:417-426.
16. http://www.tissuegenesis.com/TGI%201000%20Product%
20Brochure.pdf.
17. Hang-Fu, L., G. Marmolya, and D. H. Feiglin. 1995.
Liposuction fat-fillant implant for breast augmentation and
reconstruction. Aesthetic Plast Surg 19:427-437.
18. Klein, A. W. 2001. Skin filling. Collagen and other
injectables of the skin. Dermatol Clin 19:491-508, ix.
19. Hollenberg, C. H., and A. Vost. 1969. Regulation of DNA
synthesis in fat cells and stromal elements from rat adipose tissue.
J Clin Invest 47:2485-2498.
20. Gaben-Cogneville, A. M., Y. Aron, G. Idriss, T. Jahchan, J.
Y. Pello, and E. Swierczewski. 1983. Differentiation under the
control of insulin of rat preadipocytes in primary culture. Isolation
of homogeneous cellular fractions by gradient centrifugation. Biochim
Biophys Acta 762:437-444.
21. Glick, J. M., and S. J. Adelman. 1983. Established cell lines
from rat adipose tissue that secrete lipoprotein lipase. In Vitro
19:421-428.
22. Zuk, P. A., M. Zhu, H. Mizuno, J. Huang, J. W. Futrell, A. J.
Katz, P. Benhaim, H. P. Lorenz, and M. H. Hedrick. 2001. Multilineage
cells from human adipose tissue: implications for cell-based
therapies. Tissue Eng 7:211-228.
23. Zuk, P. A., M. Zhu, P. Ashjian, D. A. De Ugarte, J. I. Huang,
H. Mizuno, Z. C. Alfonso, J. K. Fraser, P. Benhaim, and M. H.
Hedrick. 2002. Human adipose tissue is a source of multipotent stem
cells. Mol Biol Cell 13:4279-4295.
24. Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der
Zee, T. Li, B. Witzenbichler, G. Schatteman, and J. M. Isner. 1997.
Isolation of putative progenitor endothelial cells for angiogenesis.
Science 275:964-967.
25. Rauscher, F. M., P. J. Goldschmidt-Clermont, B. H. Davis, T.
Wang, D. Gregg, P. Ramaswami, A. M. Pippen, B. H. Annex, C. Dong, and
D. A. Taylor. 2003. Aging, progenitor cell exhaustion, and
atherosclerosis. Circulation 108:457-463.
26. Sata, M., D. Fukuda, K. Tanaka, Y. Kaneda, H. Yashiro, and I.
Shirakawa. 2005. The role of circulating precursors in vascular
repair and lesion formation. J Cell Mol Med 9:557-568.
27. Miranville, A., C. Heeschen, C. Sengenes, C. A. Curat, R.
Busse, and A. Bouloumie. 2004. Improvement of postnatal
neovascularization by human adipose tissue-derived stem cells.
Circulation 110:349-355.
28. Urbich, C., and S. Dimmeler. 2005. Risk factors for coronary
artery disease, circulating endothelial progenitor cells, and the
role of HMG-CoA reductase inhibitors. Kidney Int 67:1672-1676.
29. Planat-Benard, V., J. S. Silvestre, B. Cousin, M. Andre, M.
Nibbelink, R. Tamarat, M. Clergue, C. Manneville, C. Saillan-Barreau,
M. Duriez, A. Tedgui, B. Levy, L. Penicaud, and L. Casteilla. 2004.
Plasticity of human adipose lineage cells toward endothelial cells:
physiological and therapeutic perspectives. Circulation 109:656-663.
30. Rehman, J., D. Traktuev, J. Li, S. Merfeld-Clauss, C. J. Temm-
Grove, J. E. Bovenkerk, C. L. Pell, B. H. Johnstone, R. V. Considine,
and K. L. March. 2004. Secretion of angiogenic and antiapoptotic
factors by human adipose stromal cells. Circulation 109:1292-1298.
31. Cai, L., B. H. Johnstone, T. G. Cook, Z. Liang, D. Traktuev,
K. Cornetta, D. A. Ingram, E. D. Rosen, and K. L. March. 2007.
Suppression of hepatocyte growth factor production impairs the
ability of adipose-derived stem cells to promote ischemic tissue
revascularization. Stem Cells 25:3234-3243.
32. Sumi, M., M. Sata, N. Toya, K. Yanaga, T. Ohki, and R. Nagai.
2007. Transplantation of adipose stromal cells, but not mature
adipocytes, augments ischemia-induced angiogenesis. Life Sci 80:559-
565.
33. Minana, M. D., F. Carbonell-Uberos, V. Mirabet, S. Marin, and
A. Encabo. 2008. IFATS collection: Identification of hemangioblasts
in the adult human adipose tissue. Stem Cells 26:2696-2704.
34. Astori, G., F. Vignati, S. Bardelli, M. Tubio, M. Gola, V.
Albertini, F. Bambi, G. Scali, D. Castelli, V. Rasini, G. Soldati,
and T. Moccetti. 2007. "In vitro" and multicolor phenotypic
characterization of cell subpopulations identified in fresh human
adipose tissue stromal vascular fraction and in the derived
mesenchymal stem cells. J Transl Med 5:55.
35. Varma, M. J., R. G. Breuls, T. E. Schouten, W. J. Jurgens, H.
J. Bontkes, G. J. Schuurhuis, S. M. van Ham, and F. J. van Milligen.
2007. Phenotypical and functional characterization of freshly
isolated adipose tissue-derived stem cells. Stem Cells Dev 16:91-104.
36. Ruhnke, M., H. Ungefroren, A. Nussler, F. Martin, M.
Brulport, W. Schormann, J. G. Hengstler, W. Klapper, K. Ulrichs, J.
A. Hutchinson, B. Soria, R. M. Parwaresch, P. Heeckt, B. Kremer, and
F. Fandrich. 2005. Differentiation of in vitro-modified human
peripheral blood monocytes into hepatocyte-like and pancreatic islet-
like cells. Gastroenterology 128:1774-1786.
37. Ruhnke, M., A. K. Nussler, H. Ungefroren, J. G. Hengstler, B.
Kremer, W. Hoeckh, T. Gottwald, P. Heeckt, and F. Fandrich. 2005.
Human monocyte-derived neohepatocytes: a promising alternative to
primary human hepatocytes for autologous cell therapy.
Transplantation 79:1097-1103.
38. Suganami, T., J. Nishida, and Y. Ogawa. 2005. A paracrine
loop between adipocytes and macrophages aggravates inflammatory
changes: role of free fatty acids and tumor necrosis factor alpha.
Arterioscler Thromb Vasc Biol 25:2062-2068.
39. Bastard, J. P., M. Maachi, C. Lagathu, M. J. Kim, M. Caron,
H. Vidal, J. Capeau, and B. Feve. 2006. Recent advances in the
relationship between obesity, inflammation, and insulin resistance.
Eur Cytokine Netw 17:4-12.
40. Zeyda, M., and T. M. Stulnig. 2007. Adipose tissue
macrophages. Immunol Lett 112:61-67.
41. Odegaard, J. I., R. R. Ricardo-Gonzalez, M. H. Goforth, C. R.
Morel, V. Subramanian, L. Mukundan, A. R. Eagle, D. Vats, F.
Brombacher, A. W. Ferrante, and A. Chawla. 2007. Macrophage-specific
PPARgamma controls alternative activation and improves insulin
resistance. Nature 447:1116-1120.
42. Zeyda, M., D. Farmer, J. Todoric, O. Aszmann, M. Speiser, G.
Gyori, G. J. Zlabinger, and T. M. Stulnig. 2007. Human adipose tissue
macrophages are of an anti-inflammatory phenotype but capable of
excessive pro-inflammatory mediator production. Int J Obes (Lond)
31:1420-1428.
43. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A.
Sica. 2002. Macrophage polarization: tumor-associated macrophages as
a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol
23:549-555.
44. Mehta, A., R. Brewington, M. Chatterji, M. Zoubine, G. T.
Kinasewitz, G. T. Peer, A. C. Chang, F. B. Taylor, Jr., and A.
Shnyra. 2004. Infection-induced modulation of m1 and m2 phenotypes in
circulating monocytes: role in immune monitoring and early prognosis
of sepsis. Shock 22:423-430.
45. Song, G. Y., C. S. Chung, D. Jarrar, I. H. Chaudry, and A.
Ayala. 2001. Evolution of an immune suppressive macrophage phenotype
as a product of P38 MAPK activation in polymicrobial sepsis. Shock
15:42-48.
46. Gustafsson, C., J. Mjosberg, A. Matussek, R. Geffers, L.
Matthiesen, G. Berg, S. Sharma, J. Buer, and J. Ernerudh. 2008. Gene
expression profiling of human decidual macrophages: evidence for
immunosuppressive phenotype. PLoS ONE 3:e2078.
47. Wang, Y., Y. P. Wang, G. Zheng, V. W. Lee, L. Ouyang, D. H.
Chang, D. Mahajan, J. Coombs, Y. M. Wang, S. I. Alexander, and D. C.
Harris. 2007. Ex vivo programmed macrophages ameliorate experimental
chronic inflammatory renal disease. Kidney Int 72:290-299.
48. Ponomarev, E. D., K. Maresz, Y. Tan, and B. N. Dittel. 2007.
CNS-derived interleukin-4 is essential for the regulation of
autoimmune inflammation and induces a state of alternative activation
in microglial cells. J Neurosci 27:10714-10721.
49. Zhang, X., M. Li, D. Lian, X. Zheng, Z. X. Zhang, T. E.
Ichim, X. Xia, X. Huang, C. Vladau, M. Suzuki, B. Garcia, A. M.
Jevnikar, and W. P. Min. 2008. Generation of therapeutic dendritic
cells and regulatory T cells for preventing allogeneic cardiac graft
rejection. Clin Immunol 127:313-321.
50. Ichim, T. E., R. Zhong, and W. P. Min. 2003. Prevention of
allograft rejection by in vitro generated tolerogenic dendritic
cells. Transpl Immunol 11:295-306.
51. Tiemessen, M. M., A. L. Jagger, H. G. Evans, M. J. van
Herwijnen, S. John, and L. S. Taams. 2007. CD4+CD25+Foxp3+ regulatory
T cells induce alternative activation of human monocytes/macrophages.
Proc Natl Acad Sci U S A 104:19446-19451.
52. Ryan, J. M., F. Barry, J. M. Murphy, and B. P. Mahon. 2007.
Interferon-gamma does not break, but promotes the immunosuppressive
capacity of adult human mesenchymal stem cells. Clin Exp Immunol
149:353-363.
53. Ye, Z., Y. Wang, H. Y. Xie, and S. S. Zheng. 2008.
Immunosuppressive effects of rat mesenchymal stem cells: involvement
of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int 7:608-
614.
54. Askenasy, N., A. Kaminitz, and S. Yarkoni. 2008. Mechanisms
of T regulatory cell function. Autoimmun Rev 7:370-375.
55. Gonzalez-Rey, E., M. A. Gonzalez, N. Varela, F. O'Valle, P.
Hernandez-Cortes, L. Rico, D. Buscher, and M. Delgado. 2009. Human
adipose-derived mesenchymal stem cells reduce inflammatory and T-cell
responses and induce regulatory T cells in vitro in rheumatoid
arthritis. Ann Rheum Dis.
56. Casiraghi, F., N. Azzollini, P. Cassis, B. Imberti, M.
Morigi, D. Cugini, R. A. Cavinato, M. Todeschini, S. Solini, A.
Sonzogni, N. Perico, G. Remuzzi, and M. Noris. 2008. Pretransplant
infusion of mesenchymal stem cells prolongs the survival of a
semiallogeneic heart transplant through the generation of regulatory
T cells. J Immunol 181:3933-3946.
57. Di Ianni, M., B. Del Papa, M. De Ioanni, L. Moretti, E.
Bonifacio, D. Cecchini, P. Sportoletti, F. Falzetti, and A. Tabilio.
2008. Mesenchymal cells recruit and regulate T regulatory cells. Exp
Hematol 36:309-318.
58. Zannettino, A. C., S. Paton, A. Arthur, F. Khor, S. Itescu,
J. M. Gimble, and S. Gronthos. 2008. Multipotential human adipose-
derived stromal stem cells exhibit a perivascular phenotype in vitro
and in vivo. J Cell Physiol 214:413-421.
59. Hoogduijn, M. J., M. J. Crop, A. M. Peeters, G. J. Van Osch,
A. H. Balk, J. N. Ijzermans, W. Weimar, and C. C. Baan. 2007. Human
heart, spleen, and perirenal fat-derived mesenchymal stem cells have
immunomodulatory capacities. Stem Cells Dev 16:597-604.
60. Chao, K. C., K. F. Chao, Y. S. Fu, and S. H. Liu. 2008. Islet-
like clusters derived from mesenchymal stem cells in Wharton's Jelly
of the human umbilical cord for transplantation to control type 1
diabetes. PLoS ONE 3:e1451.
61. Jo, Y. Y., H. J. Lee, S. Y. Kook, H. W. Choung, J. Y. Park,
J. H. Chung, Y. H. Choung, E. S. Kim, H. C. Yang, and P. H. Choung.
2007. Isolation and characterization of postnatal stem cells from
human dental tissues. Tissue Eng 13:767-773.
62. He, Q., C. Wan, and G. Li. 2007. Concise review: multipotent
mesenchymal stromal cells in blood. Stem Cells 25:69-77.
63. Djouad, F., L. M. Charbonnier, C. Bouffi, P. Louis-Plence, C.
Bony, F. Apparailly, C. Cantos, C. Jorgensen, and D. Noel. 2007.
Mesenchymal stem cells inhibit the differentiation of dendritic cells
through an interleukin-6-dependent mechanism. Stem Cells 25:2025-2032.
64. English, K., F. P. Barry, and B. P. Mahon. 2008. Murine
mesenchymal stem cells suppress dendritic cell migration, maturation
and antigen presentation. Immunol Lett 115:50-58.
65. Nemeth, K., A. Leelahavanichkul, P. S. Yuen, B. Mayer, A.
Parmelee, K. Doi, P. G. Robey, K. Leelahavanichkul, B. H. Koller, J.
M. Brown, X. Hu, I. Jelinek, R. A. Star, and E. Mezey. 2009. Bone
marrow stromal cells attenuate sepsis via prostaglandin E(2)-
dependent reprogramming of host macrophages to increase their
interleukin-10 production. Nat Med 15:42-49.
66. Ortiz, L. A., M. Dutreil, C. Fattman, A. C. Pandey, G.
Torres, K. Go, and D. G. Phinney. 2007. Interleukin 1 receptor
antagonist mediates the antiinflammatory and antifibrotic effect of
mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A
104:11002-11007.
67. Nasef, A., A. Chapel, C. Mazurier, S. Bouchet, M. Lopez, N.
Mathieu, L. Sensebe, Y. Zhang, N. C. Gorin, D. Thierry, and L.
Fouillard. 2007. Identification of IL-10 and TGF-beta transcripts
involved in the inhibition of T-lymphocyte proliferation during cell
contact with human mesenchymal stem cells. Gene Expr 13:217-226.
68. Karussis, D., and I. Kassis. 2008. The potential use of stem
cells in multiple sclerosis: an overview of the preclinical
experience. Clin Neurol Neurosurg 110:889-896.
69. Zappia, E., S. Casazza, E. Pedemonte, F. Benvenuto, I.
Bonanni, E. Gerdoni, D. Giunti, A. Ceravolo, F. Cazzanti, F.
Frassoni, G. Mancardi, and A. Uccelli. 2005. Mesenchymal stem cells
ameliorate experimental autoimmune encephalomyelitis inducing T-cell
anergy. Blood 106:1755-1761.
70. Boumaza, I., S. Srinivasan, W. T. Witt, C. Feghali-Bostwick,
Y. Dai, A. Garcia-Ocana, and M. Feili-Hariri. 2008. Autologous bone
marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin
expression in the islets, alter T cell cytokine pattern and preserve
regulatory T cells in the periphery and induce sustained
normoglycemia. J Autoimmun.
71. Zhou, K., H. Zhang, O. Jin, X. Feng, G. Yao, Y. Hou, and L.
Sun. 2008. Transplantation of human bone marrow mesenchymal stem cell
ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol
Immunol 5:417-424.
72. Parekkadan, B., A. W. Tilles, and M. L. Yarmush. 2008. Bone
marrow-derived mesenchymal stem cells ameliorate autoimmune
enteropathy independently of regulatory T cells. Stem Cells 26:1913-
1919.
73. Arthur, A., A. Zannettino, and S. Gronthos. 2009. The
therapeutic applications of multipotential mesenchymal/stromal stem
cells in skeletal tissue repair. J Cell Physiol 218:237-245.
74. Mishra, P. K. 2008. Bone marrow-derived mesenchymal stem
cells for treatment of heart failure: is it all paracrine actions and
immunomodulation? J Cardiovasc Med (Hagerstown) 9:122-128.
75. Centeno, C. J., D. Busse, J. Kisiday, C. Keohan, M. Freeman,
and D. Karli. 2008. Increased knee cartilage volume in degenerative
joint disease using percutaneously implanted, autologous mesenchymal
stem cells. Pain Physician 11:343-353.
76. Katritsis, D. 2008. Cellular replacement therapy for
arrhythmia treatment: early clinical experience. J Interv Card
Electrophysiol 22:99-105.
77. Slavin, S., B. G. Kurkalli, and D. Karussis. 2008. The
potential use of adult stem cells for the treatment of multiple
sclerosis and other neurodegenerative disorders. Clin Neurol
Neurosurg 110:943-946.
78. Rosati, G. 2001. The prevalence of multiple sclerosis in the
world: an update. Neurol Sci 22:117-139.
79. Pittock, S. J., and C. F. Lucchinetti. 2007. The pathology of
MS: new insights and potential clinical applications. Neurologist
13:45-56.
80. Saresella, M., I. Marventano, R. Longhi, F. Lissoni, D.
Trabattoni, L. Mendozzi, D. Caputo, and M. Clerici. 2008.
CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-
remitting multiple sclerosis and their modulation by therapy. FASEB J
22:3500-3508.
81. Korporal, M., J. Haas, B. Balint, B. Fritzsching, A. Schwarz,
S. Moeller, B. Fritz, E. Suri-Payer, and B. Wildemann. 2008.
Interferon beta-induced restoration of regulatory T-cell function in
multiple sclerosis is prompted by an increase in newly generated
naive regulatory T cells. Arch Neurol 65:1434-1439.
82. Akirav, E. M., C. M. Bergman, M. Hill, and N. H. Ruddle.
2009. Depletion of CD4(+)CD25(+) T cells exacerbates experimental
autoimmune encephalomyelitis induced by mouse, but not rat, antigens.
J Neurosci Res.
83. Reddy, J., Z. Illes, X. Zhang, J. Encinas, J. Pyrdol, L.
Nicholson, R. A. Sobel, K. W. Wucherpfennig, and V. K. Kuchroo. 2004.
Myelin proteolipid protein-specific CD4+CD25+ regulatory cells
mediate genetic resistance to experimental autoimmune
encephalomyelitis. Proc Natl Acad Sci U S A 101:15434-15439.
84. Gregg, C., V. Shikar, P. Larsen, G. Mak, A. Chojnacki, V. W.
Yong, and S. Weiss. 2007. White matter plasticity and enhanced
remyelination in the maternal CNS. J Neurosci 27:1812-1823.
85. Penner, I. K., L. Kappos, M. Rausch, K. Opwis, and E. W.
Radu. 2006. Therapy-induced plasticity of cognitive functions in MS
patients: insights from fMRI. J Physiol Paris 99:455-462.
86. Nait-Oumesmar, B., N. Picard-Riera, C. Kerninon, L. Decker,
D. Seilhean, G. U. Hoglinger, E. C. Hirsch, R. Reynolds, and A. Baron-
Van Evercooren. 2007. Activation of the subventricular zone in
multiple sclerosis: evidence for early glial progenitors. Proc Natl
Acad Sci U S A 104:4694-4699.
87. Kassis, I., N. Grigoriadis, B. Gowda-Kurkalli, R. Mizrachi-
Kol, T. Ben-Hur, S. Slavin, O. Abramsky, and D. Karussis. 2008.
Neuroprotection and immunomodulation with mesenchymal stem cells in
chronic experimental autoimmune encephalomyelitis. Arch Neurol 65:753-
761.
88. Bai, L., D. P. Lennon, V. Eaton, K. Maier, A. I. Caplan, S.
D. Miller, and R. H. Miller. 2009. Human bone marrow-derived
mesenchymal stem cells induce Th2-polarized immune response and
promote endogenous repair in animal models of multiple sclerosis.
Glia.
89. Mohyeddin Bonab, M., S. Yazdanbakhsh, J. Lotfi, K.
Alimoghaddom, F. Talebian, F. Hooshmand, A. Ghavamzadeh, and B.
Nikbin. 2007. Does mesenchymal stem cell therapy help multiple
sclerosis patients? Report of a pilot study. Iran J Immunol 4:50-57.
90. Martino, G., R. Furlan, E. Brambilla, A. Bergami, F. Ruffini,
M. Gironi, P. L. Poliani, L. M. Grimaldi, and G. Comi. 2000.
Cytokines and immunity in multiple sclerosis: the dual signal
hypothesis. J Neuroimmunol 109:3-9.
91. Hafler, D. A., J. M. Slavik, D. E. Anderson, K. C. O'Connor,
P. De Jager, and C. Baecher-Allan. 2005. Multiple sclerosis. Immunol
Rev 204:208-231.
92. Viglietta, V., C. Baecher-Allan, H. L. Weiner, and D. A.
Hafler. 2004. Loss of functional suppression by CD4+CD25+ regulatory
T cells in patients with multiple sclerosis. J Exp Med 199:971-979.
93. Kornek, B., and H. Lassmann. 2003. Neuropathology of multiple
sclerosis-new concepts. Brain Res Bull 61:321-326.
94. Kornek, B., M. K. Storch, R. Weissert, E. Wallstroem, A.
Stefferl, T. Olsson, C. Linington, M. Schmidbauer, and H. Lassmann.
2000. Multiple sclerosis and chronic autoimmune encephalomyelitis: a
comparative quantitative study of axonal injury in active, inactive,
and remyelinated lesions. Am J Pathol 157:267-276.





--- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@...> wrote:
>
> I was referring to stem cells taken from Adipose tissue which is
> being used to treat many diagnosis'.  I use the word "treat"
lightly.
> Do you remember a few years ago when it all began...shark stem
cells
> being given to humans for an array of issues.  Then came the pigs.
> There is no evidence to lead one to think adipose stem cells will
> improve any disorder much less one as complex as MS which involves
> the brain and the entire nervous system of the body.  What MS
> patients need are partcular subset of stem cells namely CD1333 and
> CD34.  For best results boost these with MSC's which are found in
the
> highest concentraition in the bone marrow.
> K
>
> --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> <thomas.ichim@> wrote:
> >
> > Are you talking about autologous fat for crohn's being a "fad"?
> >
> > or about Costa Rica?
> >
> >
> >
> > --- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@>
wrote:
> > >
> > > There are "fads" even in the stem cell world and this is an
> example
> > > of yet another treatment designed to line the pockets.  This
> > > treatment was created a couple of years ago but not much has
been
> > > reported about it because it has shown so little promise.
> > > Buyer beware.
> > >
> > > --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> > > <thomas.ichim@> wrote:
> > > >
> > > > did you guys see they also are doing autologous fat for MS in
> > Costa
> > > > Rica?
> > > >
> > > > http://www.youtube.com/watch?v=k3Z1J3QmYoE
> > > >
> > > >
> > > >
> > > > --- In stemcellsafety@yahoogroups.com, "Kirshner Ross-Vaden"
> > > > <kirsh@> wrote:
> > > > >
> > > > >
> > > > > Stem Cell Treatment For Crohn's Disease
> > > > >
> > > > >
> > > > > Article Date: 21 Feb 2009 - 0:00 PST
> > > > >
> > > > >
> > > > >
> > > > >   _____
> > > > >
> > > > >
> > > > > Cellular therapy with stem cells
> > > > >
> > > >
> > >
> >
>
<http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>
> > > >  is
> > > > > revolutionizing the focus of treatment of many serious
> > diseases.
> > > > Replacing
> > > > > the cells of damaged tissue with other new cells from the
> same
> > > > patient is
> > > > > already a reality. This is the basis of cellular therapy
and
> > > > regenerative
> > > > > medicine, the latest great advance in biomedicine. In this
> > line,
> > > > Hospital
> > > > > Clínic, Barcelona is leading the world in the application
of
> an
> > > > innovative
> > > > > cellular therapy that uses stem cells to treat Crohn's
> disease,
> > a
> > > > chronic
> > > > > genetic disease that affects 1% of the population in Spain
> and
> > > > which has
> > > > > considerable impact on the quality of life of the patients.
> The
> > > > procedure is
> > > > > based on an autologous bone-marrow transplant (when
patients
> > > > receive a
> > > > > transplant of their own stem cells) and now constitutes a
> > > treatment
> > > > option
> > > > > to cure an intestinal disease that sometimes does not
> > > successfully
> > > > respond
> > > > > to drugs and requires highly complex surgery that does not
> > > provide
> > > > a cure.
> > > > >
> > > > > Hospital Clínic, Barcelona is one of the few hospitals in
the
> > > world
> > > > to apply
> > > > > this new therapeutic option for patients with Crohn's
> disease,
> > > and
> > > > it does
> > > > > so with the guarantee of success experienced in the US and
> > Italy,
> > > > where the
> > > > > technique has been tested with excellent results: in an
> average
> > > > follow-up
> > > > > period of 6 years, 80% of transplant patients are in a
phase
> of
> > > > total
> > > > > remission of the disease and the remaining 20% have shown
> > > > considerable
> > > > > improvement following the transplant, and are now
responding
> > > > favorably to
> > > > > drugs. Dr. Julián Panés and Dr. Elena Ricart over the
> > > > Gastroenterology
> > > > > Department of Hospital Clínic, Barcelona are the driving
> force
> > > > behind this
> > > > > therapy in Spain and began to implement regenerative
cellular
> > > > therapy in
> > > > > patients with Crohn's disease in August 2008. To date, a
> total
> > of
> > > 6
> > > > patients
> > > > > are benefiting from this new treatment, of whom 3 I've
> already
> > > > completed the
> > > > > process and are in the follow-up face, and a further 3 are
at
> > > > different
> > > > > stages of therapy. The transplant requires several weeks of
> > > > admission to
> > > > > hospital before patients receive their own cells.
> > > > >
> > > > > The success of autologous stem-cell transplants in Crohn's
> > > disease
> > > > is
> > > > > possible thanks to the joint collaboration of the
> > > gastroenterology
> > > > and
> > > > > hematology departments and of the hemotherapy and
hemostasis
> > > > department, as
> > > > > the procedure is the same as that carried out in bone-
morrow
> > > > transplants to
> > > > > cure leukemia or myeloma. Thus, when a case is detected,
the
> > > > professionals
> > > > > from the different departments of Hospital Clinic,
Barcelona
> > > > supervise each
> > > > > of the phases of the process to autologous Transplant. In
> this
> > > > case, Dr.
> > > > > Panés and Dr. Ricart from the gastroenterology department
> work
> > > > together with
> > > > > Dr. Montserrat Rovira from the hematology department of the
> > > Catalan
> > > > hospital
> > > > > and with Dr. Enric Carreras, the head of this department,
to
> > > > provide joint
> > > > > monitoring of the patients. Dr. Pedro Marín of the
> hemotherapy
> > and
> > > > > hemostasis department of Hospital Clínic, together with Dr.
> > > Miquel
> > > > Lozano,
> > > > > are responsible for guiding the patients through the
process
> of
> > > > > cryopreservation and collection of stem cells before the
> final
> > > > transplant.
> > > > >
> > > > > Cellular Therapy as a Strategy to Combat Crohn's Disease
> > > > >
> > > > > Crohn's disease, together with ulcerative colitis, is
> included
> > in
> > > > what is
> > > > > called irritable bowel disease. It is a chronic genetic
> disease
> > > > that occurs
> > > > > when the immune system loses tolerance to the patient's own
> > > > intestinal
> > > > > flora, leading to an abnormal inflammatory response that
> > > continues
> > > > over
> > > > > time. The results are inflammation and ulceration in
> different
> > > > areas of the
> > > > > digestive tract, leading to the symptoms. The disease
> > progresses
> > > in
> > > > the form
> > > > > of unpredictable and variable outbreaks throughout the
> > patient's
> > > > life and
> > > > > the severity of the symptoms varies according to the level
of
> > > > involvement of
> > > > > the intestines and the patient's response to the assigned
> > > > treatment. It is a
> > > > > disease that usually affects young people between the ages
of
> > 18
> > > > and 40
> > > > > years, and approximately 2000 new cases are diagnosed in
> Spain
> > > > every year.
> > > > > Diagnosis is often difficult because it presents symptoms
> > similar
> > > > to those
> > > > > of other diseases of the digestive tract: abdominal pain,
> > > diarrhea,
> > > > > vomiting, nausea, fever, general malaise, etc. Patients'
> > quality
> > > of
> > > > life is
> > > > > conditioned by the severity of the disease and, in the most
> > > severe
> > > > cases,
> > > > > prevents them from leading a normal life, with a very high
> > level
> > > of
> > > > > suffering due to the acuteness and frequency of the
> intestinal
> > > > symptoms.
> > > > >
> > > > > Hospital Clínic de Barcelona is one of the few hospitals in
> the
> > > > world to
> > > > > instate cellular therapy using autologous stem-cell
> > > > transplantation. In the
> > > > > US, the treatment has been tested on 12 patients with
severe
> > > Crohn's
> > > > > disease, of whom 11 have had very good results; in Italy,
the
> > > > treatment has
> > > > > been applied to 4 patients, 3 of whom are also showing
> > excellent
> > > > progress
> > > > > following the transplant. As Hospital Clínic, 6 patients
with
> > > > Crohn's
> > > > > disease are already included in the process and, following
> the
> > > > international
> > > > > examples, increasing numbers of patients are expected to
> choose
> > > > this option
> > > > > to treat the disease in a state that was, to date,
> practically
> > > > untreatable.
> > > > >
> > > > > In severe cases involving recurrent outbreaks (reactivation
> of
> > > the
> > > > disease
> > > > > several times throughout the patient's life), Crohn's
disease
> > > > presents
> > > > > several treatment options. Firstly, doctors choose to use
> > > > corticosteroids
> > > > > and immunosuppressant and biological drugs to control the
> > > > inflammatory
> > > > > process and prevent complications of the disease such as
> > stenosis
> > > > (narrowing
> > > > > of the intestinal lumen) or fistulas (openings from the
> > > intestinal
> > > > lumen to
> > > > > other organs, such as the intestine, bladder, vagina, or
> skin).
> > > > However,
> > > > > over the course of the disease, as much as 70% of severe
> > patients
> > > > require
> > > > > surgery to remove segments affected by the disease, due to
> > > failure
> > > > of the
> > > > > pharmacologic approach. The surgery is occasionally very
> > > aggressive
> > > > for the
> > > > > patient, as it is sometimes necessary to remove the entire
> > colon
> > > or
> > > > large
> > > > > sections of the small intestine, thereby considerably
> affecting
> > > the
> > > > > absorption of food by the intestine, with a resulting
> > > deterioration
> > > > in
> > > > > quality of life and body image (colostomy bag). For this
> > reason,
> > > new
> > > > > treatments are being developed for patients in whom this
> > solution
> > > > has not
> > > > > been an option to date.
> > > > >
> > > > > Autologous Stem-Cell Transplant: Phases of the Procedure
> > > > >
> > > > > When the case is detected (that does not respond to drugs
or
> > > > surgery), the
> > > > > patient undergoes an autologous stem-cell transplant, which
> is
> > a
> > > > bone-morrow
> > > > > transplant in which the immune system is reset to prevent
it
> > from
> > > > attacking
> > > > > the intestinal flora. The process lasts approximately 2
> months
> > > and
> > > > consists
> > > > > of 6 phases:
> > > > >
> > > > > 1. Initial Chemotherapy (Cyclophosphamide + G-CSF). In
> > this
> > > > initial
> > > > > phase, leukopenia or reduction of the number of leukocytes
> > > (immune-
> > > > system
> > > > > cells) in the blood is induced in the patient.
> > > > > 2. Migration of Stem-Cells to the Blood. Following the
> > previous
> > > > > immunosuppression, the organism reacts by releasing stem
> cells
> > > from
> > > > the bone
> > > > > marrow into the blood; these are the cells which will later
> be
> > > used
> > > > for the
> > > > > transplant.
> > > > > 3. Collection of Stem Cells by means of Apheresis.
> > Apheresis is a
> > > > > technique that separates components of the blood. Here, the
> > stem
> > > > cells that
> > > > > previously migrated from the bone marrow are separated.
> > > > > 4. Cryopreservation of Stem Cells. When the stem cells
> > have been
> > > > > collected by apheresis, they are frozen and preserved until
> > ready
> > > > for
> > > > > transplant.
> > > > > 5. Second Chemotherapy. In this phase, total leukopenia
> > is
> > > > induced;
> > > > > that is, the immune system is left devoid of leukocytes,
> ready
> > to
> > > > be reset
> > > > > with the stem-cell transplant.
> > > > > 6. Autologous Stem-Cell Transplant. The patient receives
> > the
> > > > transplant
> > > > > by means of transfusion with his or her own stem cells. The
> > > immune
> > > > system is
> > > > > reset, leading to remission or reduction of the abnormal
> > > > inflammatory
> > > > > process of Crohn's disease.
> > > > >
> > > >
> > >
> >
>

I was referring to stem cells taken from Adipose tissue which is
being used to treat many diagnosis'.  I use the word "treat" lightly.
Do you remember a few years ago when it all began...shark stem cells
being given to humans for an array of issues.  Then came the pigs.
There is no evidence to lead one to think adipose stem cells will
improve any disorder much less one as complex as MS which involves
the brain and the entire nervous system of the body.  What MS
patients need are partcular subset of stem cells namely CD1333 and
CD34.  For best results boost these with MSC's which are found in the
highest concentraition in the bone marrow.
K

--- In stemcellsafety@yahoogroups.com, "xenovaxforever"
<thomas.ichim@...> wrote:
>
> Are you talking about autologous fat for crohn's being a "fad"?
>
> or about Costa Rica?
>
>
>
> --- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@> wrote:
> >
> > There are "fads" even in the stem cell world and this is an
example
> > of yet another treatment designed to line the pockets.  This
> > treatment was created a couple of years ago but not much has been
> > reported about it because it has shown so little promise.
> > Buyer beware.
> >
> > --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> > <thomas.ichim@> wrote:
> > >
> > > did you guys see they also are doing autologous fat for MS in
> Costa
> > > Rica?
> > >
> > > http://www.youtube.com/watch?v=k3Z1J3QmYoE
> > >
> > >
> > >
> > > --- In stemcellsafety@yahoogroups.com, "Kirshner Ross-Vaden"
> > > <kirsh@> wrote:
> > > >
> > > >
> > > > Stem Cell Treatment For Crohn's Disease
> > > >
> > > >
> > > > Article Date: 21 Feb 2009 - 0:00 PST
> > > >
> > > >
> > > >
> > > >   _____
> > > >
> > > >
> > > > Cellular therapy with stem cells
> > > >
> > >
> >
>
<http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>
> > >  is
> > > > revolutionizing the focus of treatment of many serious
> diseases.
> > > Replacing
> > > > the cells of damaged tissue with other new cells from the
same
> > > patient is
> > > > already a reality. This is the basis of cellular therapy and
> > > regenerative
> > > > medicine, the latest great advance in biomedicine. In this
> line,
> > > Hospital
> > > > Clínic, Barcelona is leading the world in the application of
an
> > > innovative
> > > > cellular therapy that uses stem cells to treat Crohn's
disease,
> a
> > > chronic
> > > > genetic disease that affects 1% of the population in Spain
and
> > > which has
> > > > considerable impact on the quality of life of the patients.
The
> > > procedure is
> > > > based on an autologous bone-marrow transplant (when patients
> > > receive a
> > > > transplant of their own stem cells) and now constitutes a
> > treatment
> > > option
> > > > to cure an intestinal disease that sometimes does not
> > successfully
> > > respond
> > > > to drugs and requires highly complex surgery that does not
> > provide
> > > a cure.
> > > >
> > > > Hospital Clínic, Barcelona is one of the few hospitals in the
> > world
> > > to apply
> > > > this new therapeutic option for patients with Crohn's
disease,
> > and
> > > it does
> > > > so with the guarantee of success experienced in the US and
> Italy,
> > > where the
> > > > technique has been tested with excellent results: in an
average
> > > follow-up
> > > > period of 6 years, 80% of transplant patients are in a phase
of
> > > total
> > > > remission of the disease and the remaining 20% have shown
> > > considerable
> > > > improvement following the transplant, and are now responding
> > > favorably to
> > > > drugs. Dr. Julián Panés and Dr. Elena Ricart over the
> > > Gastroenterology
> > > > Department of Hospital Clínic, Barcelona are the driving
force
> > > behind this
> > > > therapy in Spain and began to implement regenerative cellular
> > > therapy in
> > > > patients with Crohn's disease in August 2008. To date, a
total
> of
> > 6
> > > patients
> > > > are benefiting from this new treatment, of whom 3 I've
already
> > > completed the
> > > > process and are in the follow-up face, and a further 3 are at
> > > different
> > > > stages of therapy. The transplant requires several weeks of
> > > admission to
> > > > hospital before patients receive their own cells.
> > > >
> > > > The success of autologous stem-cell transplants in Crohn's
> > disease
> > > is
> > > > possible thanks to the joint collaboration of the
> > gastroenterology
> > > and
> > > > hematology departments and of the hemotherapy and hemostasis
> > > department, as
> > > > the procedure is the same as that carried out in bone-morrow
> > > transplants to
> > > > cure leukemia or myeloma. Thus, when a case is detected, the
> > > professionals
> > > > from the different departments of Hospital Clinic, Barcelona
> > > supervise each
> > > > of the phases of the process to autologous Transplant. In
this
> > > case, Dr.
> > > > Panés and Dr. Ricart from the gastroenterology department
work
> > > together with
> > > > Dr. Montserrat Rovira from the hematology department of the
> > Catalan
> > > hospital
> > > > and with Dr. Enric Carreras, the head of this department, to
> > > provide joint
> > > > monitoring of the patients. Dr. Pedro Marín of the
hemotherapy
> and
> > > > hemostasis department of Hospital Clínic, together with Dr.
> > Miquel
> > > Lozano,
> > > > are responsible for guiding the patients through the process
of
> > > > cryopreservation and collection of stem cells before the
final
> > > transplant.
> > > >
> > > > Cellular Therapy as a Strategy to Combat Crohn's Disease
> > > >
> > > > Crohn's disease, together with ulcerative colitis, is
included
> in
> > > what is
> > > > called irritable bowel disease. It is a chronic genetic
disease
> > > that occurs
> > > > when the immune system loses tolerance to the patient's own
> > > intestinal
> > > > flora, leading to an abnormal inflammatory response that
> > continues
> > > over
> > > > time. The results are inflammation and ulceration in
different
> > > areas of the
> > > > digestive tract, leading to the symptoms. The disease
> progresses
> > in
> > > the form
> > > > of unpredictable and variable outbreaks throughout the
> patient's
> > > life and
> > > > the severity of the symptoms varies according to the level of
> > > involvement of
> > > > the intestines and the patient's response to the assigned
> > > treatment. It is a
> > > > disease that usually affects young people between the ages of
> 18
> > > and 40
> > > > years, and approximately 2000 new cases are diagnosed in
Spain
> > > every year.
> > > > Diagnosis is often difficult because it presents symptoms
> similar
> > > to those
> > > > of other diseases of the digestive tract: abdominal pain,
> > diarrhea,
> > > > vomiting, nausea, fever, general malaise, etc. Patients'
> quality
> > of
> > > life is
> > > > conditioned by the severity of the disease and, in the most
> > severe
> > > cases,
> > > > prevents them from leading a normal life, with a very high
> level
> > of
> > > > suffering due to the acuteness and frequency of the
intestinal
> > > symptoms.
> > > >
> > > > Hospital Clínic de Barcelona is one of the few hospitals in
the
> > > world to
> > > > instate cellular therapy using autologous stem-cell
> > > transplantation. In the
> > > > US, the treatment has been tested on 12 patients with severe
> > Crohn's
> > > > disease, of whom 11 have had very good results; in Italy, the
> > > treatment has
> > > > been applied to 4 patients, 3 of whom are also showing
> excellent
> > > progress
> > > > following the transplant. As Hospital Clínic, 6 patients with
> > > Crohn's
> > > > disease are already included in the process and, following
the
> > > international
> > > > examples, increasing numbers of patients are expected to
choose
> > > this option
> > > > to treat the disease in a state that was, to date,
practically
> > > untreatable.
> > > >
> > > > In severe cases involving recurrent outbreaks (reactivation
of
> > the
> > > disease
> > > > several times throughout the patient's life), Crohn's disease
> > > presents
> > > > several treatment options. Firstly, doctors choose to use
> > > corticosteroids
> > > > and immunosuppressant and biological drugs to control the
> > > inflammatory
> > > > process and prevent complications of the disease such as
> stenosis
> > > (narrowing
> > > > of the intestinal lumen) or fistulas (openings from the
> > intestinal
> > > lumen to
> > > > other organs, such as the intestine, bladder, vagina, or
skin).
> > > However,
> > > > over the course of the disease, as much as 70% of severe
> patients
> > > require
> > > > surgery to remove segments affected by the disease, due to
> > failure
> > > of the
> > > > pharmacologic approach. The surgery is occasionally very
> > aggressive
> > > for the
> > > > patient, as it is sometimes necessary to remove the entire
> colon
> > or
> > > large
> > > > sections of the small intestine, thereby considerably
affecting
> > the
> > > > absorption of food by the intestine, with a resulting
> > deterioration
> > > in
> > > > quality of life and body image (colostomy bag). For this
> reason,
> > new
> > > > treatments are being developed for patients in whom this
> solution
> > > has not
> > > > been an option to date.
> > > >
> > > > Autologous Stem-Cell Transplant: Phases of the Procedure
> > > >
> > > > When the case is detected (that does not respond to drugs or
> > > surgery), the
> > > > patient undergoes an autologous stem-cell transplant, which
is
> a
> > > bone-morrow
> > > > transplant in which the immune system is reset to prevent it
> from
> > > attacking
> > > > the intestinal flora. The process lasts approximately 2
months
> > and
> > > consists
> > > > of 6 phases:
> > > >
> > > > 1. Initial Chemotherapy (Cyclophosphamide + G-CSF). In
> this
> > > initial
> > > > phase, leukopenia or reduction of the number of leukocytes
> > (immune-
> > > system
> > > > cells) in the blood is induced in the patient.
> > > > 2. Migration of Stem-Cells to the Blood. Following the
> previous
> > > > immunosuppression, the organism reacts by releasing stem
cells
> > from
> > > the bone
> > > > marrow into the blood; these are the cells which will later
be
> > used
> > > for the
> > > > transplant.
> > > > 3. Collection of Stem Cells by means of Apheresis.
> Apheresis is a
> > > > technique that separates components of the blood. Here, the
> stem
> > > cells that
> > > > previously migrated from the bone marrow are separated.
> > > > 4. Cryopreservation of Stem Cells. When the stem cells
> have been
> > > > collected by apheresis, they are frozen and preserved until
> ready
> > > for
> > > > transplant.
> > > > 5. Second Chemotherapy. In this phase, total leukopenia
> is
> > > induced;
> > > > that is, the immune system is left devoid of leukocytes,
ready
> to
> > > be reset
> > > > with the stem-cell transplant.
> > > > 6. Autologous Stem-Cell Transplant. The patient receives
> the
> > > transplant
> > > > by means of transfusion with his or her own stem cells. The
> > immune
> > > system is
> > > > reset, leading to remission or reduction of the abnormal
> > > inflammatory
> > > > process of Crohn's disease.
> > > >
> > >
> >
>

Are you talking about autologous fat for crohn's being a "fad"?

or about Costa Rica?



--- In stemcellsafety@yahoogroups.com, "kirshvaden" <kirsh@...> wrote:
>
> There are "fads" even in the stem cell world and this is an example
> of yet another treatment designed to line the pockets.  This
> treatment was created a couple of years ago but not much has been
> reported about it because it has shown so little promise.
> Buyer beware.
>
> --- In stemcellsafety@yahoogroups.com, "xenovaxforever"
> <thomas.ichim@> wrote:
> >
> > did you guys see they also are doing autologous fat for MS in
Costa
> > Rica?
> >
> > http://www.youtube.com/watch?v=k3Z1J3QmYoE
> >
> >
> >
> > --- In stemcellsafety@yahoogroups.com, "Kirshner Ross-Vaden"
> > <kirsh@> wrote:
> > >
> > >
> > > Stem Cell Treatment For Crohn's Disease
> > >
> > >
> > > Article Date: 21 Feb 2009 - 0:00 PST
> > >
> > >
> > >
> > >   _____
> > >
> > >
> > > Cellular therapy with stem cells
> > >
> >
>
<http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>
> >  is
> > > revolutionizing the focus of treatment of many serious
diseases.
> > Replacing
> > > the cells of damaged tissue with other new cells from the same
> > patient is
> > > already a reality. This is the basis of cellular therapy and
> > regenerative
> > > medicine, the latest great advance in biomedicine. In this
line,
> > Hospital
> > > Clínic, Barcelona is leading the world in the application of an
> > innovative
> > > cellular therapy that uses stem cells to treat Crohn's disease,
a
> > chronic
> > > genetic disease that affects 1% of the population in Spain and
> > which has
> > > considerable impact on the quality of life of the patients. The
> > procedure is
> > > based on an autologous bone-marrow transplant (when patients
> > receive a
> > > transplant of their own stem cells) and now constitutes a
> treatment
> > option
> > > to cure an intestinal disease that sometimes does not
> successfully
> > respond
> > > to drugs and requires highly complex surgery that does not
> provide
> > a cure.
> > >
> > > Hospital Clínic, Barcelona is one of the few hospitals in the
> world
> > to apply
> > > this new therapeutic option for patients with Crohn's disease,
> and
> > it does
> > > so with the guarantee of success experienced in the US and
Italy,
> > where the
> > > technique has been tested with excellent results: in an average
> > follow-up
> > > period of 6 years, 80% of transplant patients are in a phase of
> > total
> > > remission of the disease and the remaining 20% have shown
> > considerable
> > > improvement following the transplant, and are now responding
> > favorably to
> > > drugs. Dr. Julián Panés and Dr. Elena Ricart over the
> > Gastroenterology
> > > Department of Hospital Clínic, Barcelona are the driving force
> > behind this
> > > therapy in Spain and began to implement regenerative cellular
> > therapy in
> > > patients with Crohn's disease in August 2008. To date, a total
of
> 6
> > patients
> > > are benefiting from this new treatment, of whom 3 I've already
> > completed the
> > > process and are in the follow-up face, and a further 3 are at
> > different
> > > stages of therapy. The transplant requires several weeks of
> > admission to
> > > hospital before patients receive their own cells.
> > >
> > > The success of autologous stem-cell transplants in Crohn's
> disease
> > is
> > > possible thanks to the joint collaboration of the
> gastroenterology
> > and
> > > hematology departments and of the hemotherapy and hemostasis
> > department, as
> > > the procedure is the same as that carried out in bone-morrow
> > transplants to
> > > cure leukemia or myeloma. Thus, when a case is detected, the
> > professionals
> > > from the different departments of Hospital Clinic, Barcelona
> > supervise each
> > > of the phases of the process to autologous Transplant. In this
> > case, Dr.
> > > Panés and Dr. Ricart from the gastroenterology department work
> > together with
> > > Dr. Montserrat Rovira from the hematology department of the
> Catalan
> > hospital
> > > and with Dr. Enric Carreras, the head of this department, to
> > provide joint
> > > monitoring of the patients. Dr. Pedro Marín of the hemotherapy
and
> > > hemostasis department of Hospital Clínic, together with Dr.
> Miquel
> > Lozano,
> > > are responsible for guiding the patients through the process of
> > > cryopreservation and collection of stem cells before the final
> > transplant.
> > >
> > > Cellular Therapy as a Strategy to Combat Crohn's Disease
> > >
> > > Crohn's disease, together with ulcerative colitis, is included
in
> > what is
> > > called irritable bowel disease. It is a chronic genetic disease
> > that occurs
> > > when the immune system loses tolerance to the patient's own
> > intestinal
> > > flora, leading to an abnormal inflammatory response that
> continues
> > over
> > > time. The results are inflammation and ulceration in different
> > areas of the
> > > digestive tract, leading to the symptoms. The disease
progresses
> in
> > the form
> > > of unpredictable and variable outbreaks throughout the
patient's
> > life and
> > > the severity of the symptoms varies according to the level of
> > involvement of
> > > the intestines and the patient's response to the assigned
> > treatment. It is a
> > > disease that usually affects young people between the ages of
18
> > and 40
> > > years, and approximately 2000 new cases are diagnosed in Spain
> > every year.
> > > Diagnosis is often difficult because it presents symptoms
similar
> > to those
> > > of other diseases of the digestive tract: abdominal pain,
> diarrhea,
> > > vomiting, nausea, fever, general malaise, etc. Patients'
quality
> of
> > life is
> > > conditioned by the severity of the disease and, in the most
> severe
> > cases,
> > > prevents them from leading a normal life, with a very high
level
> of
> > > suffering due to the acuteness and frequency of the intestinal
> > symptoms.
> > >
> > > Hospital Clínic de Barcelona is one of the few hospitals in the
> > world to
> > > instate cellular therapy using autologous stem-cell
> > transplantation. In the
> > > US, the treatment has been tested on 12 patients with severe
> Crohn's
> > > disease, of whom 11 have had very good results; in Italy, the
> > treatment has
> > > been applied to 4 patients, 3 of whom are also showing
excellent
> > progress
> > > following the transplant. As Hospital Clínic, 6 patients with
> > Crohn's
> > > disease are already included in the process and, following the
> > international
> > > examples, increasing numbers of patients are expected to choose
> > this option
> > > to treat the disease in a state that was, to date, practically
> > untreatable.
> > >
> > > In severe cases involving recurrent outbreaks (reactivation of
> the
> > disease
> > > several times throughout the patient's life), Crohn's disease
> > presents
> > > several treatment options. Firstly, doctors choose to use
> > corticosteroids
> > > and immunosuppressant and biological drugs to control the
> > inflammatory
> > > process and prevent complications of the disease such as
stenosis
> > (narrowing
> > > of the intestinal lumen) or fistulas (openings from the
> intestinal
> > lumen to
> > > other organs, such as the intestine, bladder, vagina, or skin).
> > However,
> > > over the course of the disease, as much as 70% of severe
patients
> > require
> > > surgery to remove segments affected by the disease, due to
> failure
> > of the
> > > pharmacologic approach. The surgery is occasionally very
> aggressive
> > for the
> > > patient, as it is sometimes necessary to remove the entire
colon
> or
> > large
> > > sections of the small intestine, thereby considerably affecting
> the
> > > absorption of food by the intestine, with a resulting
> deterioration
> > in
> > > quality of life and body image (colostomy bag). For this
reason,
> new
> > > treatments are being developed for patients in whom this
solution
> > has not
> > > been an option to date.
> > >
> > > Autologous Stem-Cell Transplant: Phases of the Procedure
> > >
> > > When the case is detected (that does not respond to drugs or
> > surgery), the
> > > patient undergoes an autologous stem-cell transplant, which is
a
> > bone-morrow
> > > transplant in which the immune system is reset to prevent it
from
> > attacking
> > > the intestinal flora. The process lasts approximately 2 months
> and
> > consists
> > > of 6 phases:
> > >
> > > 1. Initial Chemotherapy (Cyclophosphamide + G-CSF). In
this
> > initial
> > > phase, leukopenia or reduction of the number of leukocytes
> (immune-
> > system
> > > cells) in the blood is induced in the patient.
> > > 2. Migration of Stem-Cells to the Blood. Following the
previous
> > > immunosuppression, the organism reacts by releasing stem cells
> from
> > the bone
> > > marrow into the blood; these are the cells which will later be
> used
> > for the
> > > transplant.
> > > 3. Collection of Stem Cells by means of Apheresis.
Apheresis is a
> > > technique that separates components of the blood. Here, the
stem
> > cells that
> > > previously migrated from the bone marrow are separated.
> > > 4. Cryopreservation of Stem Cells. When the stem cells
have been
> > > collected by apheresis, they are frozen and preserved until
ready
> > for
> > > transplant.
> > > 5. Second Chemotherapy. In this phase, total leukopenia
is
> > induced;
> > > that is, the immune system is left devoid of leukocytes, ready
to
> > be reset
> > > with the stem-cell transplant.
> > > 6. Autologous Stem-Cell Transplant. The patient receives
the
> > transplant
> > > by means of transfusion with his or her own stem cells. The
> immune
> > system is
> > > reset, leading to remission or reduction of the abnormal
> > inflammatory
> > > process of Crohn's disease.
> > >
> >
>

There are "fads" even in the stem cell world and this is an example
of yet another treatment designed to line the pockets.  This
treatment was created a couple of years ago but not much has been
reported about it because it has shown so little promise.
Buyer beware.

--- In stemcellsafety@yahoogroups.com, "xenovaxforever"
<thomas.ichim@...> wrote:
>
> did you guys see they also are doing autologous fat for MS in Costa
> Rica?
>
> http://www.youtube.com/watch?v=k3Z1J3QmYoE
>
>
>
> --- In stemcellsafety@yahoogroups.com, "Kirshner Ross-Vaden"
> <kirsh@> wrote:
> >
> >
> > Stem Cell Treatment For Crohn's Disease
> >
> >
> > Article Date: 21 Feb 2009 - 0:00 PST
> >
> >
> >
> >   _____
> >
> >
> > Cellular therapy with stem cells
> >
>
<http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>
>  is
> > revolutionizing the focus of treatment of many serious diseases.
> Replacing
> > the cells of damaged tissue with other new cells from the same
> patient is
> > already a reality. This is the basis of cellular therapy and
> regenerative
> > medicine, the latest great advance in biomedicine. In this line,
> Hospital
> > Clínic, Barcelona is leading the world in the application of an
> innovative
> > cellular therapy that uses stem cells to treat Crohn's disease, a
> chronic
> > genetic disease that affects 1% of the population in Spain and
> which has
> > considerable impact on the quality of life of the patients. The
> procedure is
> > based on an autologous bone-marrow transplant (when patients
> receive a
> > transplant of their own stem cells) and now constitutes a
treatment
> option
> > to cure an intestinal disease that sometimes does not
successfully
> respond
> > to drugs and requires highly complex surgery that does not
provide
> a cure.
> >
> > Hospital Clínic, Barcelona is one of the few hospitals in the
world
> to apply
> > this new therapeutic option for patients with Crohn's disease,
and
> it does
> > so with the guarantee of success experienced in the US and Italy,
> where the
> > technique has been tested with excellent results: in an average
> follow-up
> > period of 6 years, 80% of transplant patients are in a phase of
> total
> > remission of the disease and the remaining 20% have shown
> considerable
> > improvement following the transplant, and are now responding
> favorably to
> > drugs. Dr. Julián Panés and Dr. Elena Ricart over the
> Gastroenterology
> > Department of Hospital Clínic, Barcelona are the driving force
> behind this
> > therapy in Spain and began to implement regenerative cellular
> therapy in
> > patients with Crohn's disease in August 2008. To date, a total of
6
> patients
> > are benefiting from this new treatment, of whom 3 I've already
> completed the
> > process and are in the follow-up face, and a further 3 are at
> different
> > stages of therapy. The transplant requires several weeks of
> admission to
> > hospital before patients receive their own cells.
> >
> > The success of autologous stem-cell transplants in Crohn's
disease
> is
> > possible thanks to the joint collaboration of the
gastroenterology
> and
> > hematology departments and of the hemotherapy and hemostasis
> department, as
> > the procedure is the same as that carried out in bone-morrow
> transplants to
> > cure leukemia or myeloma. Thus, when a case is detected, the
> professionals
> > from the different departments of Hospital Clinic, Barcelona
> supervise each
> > of the phases of the process to autologous Transplant. In this
> case, Dr.
> > Panés and Dr. Ricart from the gastroenterology department work
> together with
> > Dr. Montserrat Rovira from the hematology department of the
Catalan
> hospital
> > and with Dr. Enric Carreras, the head of this department, to
> provide joint
> > monitoring of the patients. Dr. Pedro Marín of the hemotherapy and
> > hemostasis department of Hospital Clínic, together with Dr.
Miquel
> Lozano,
> > are responsible for guiding the patients through the process of
> > cryopreservation and collection of stem cells before the final
> transplant.
> >
> > Cellular Therapy as a Strategy to Combat Crohn's Disease
> >
> > Crohn's disease, together with ulcerative colitis, is included in
> what is
> > called irritable bowel disease. It is a chronic genetic disease
> that occurs
> > when the immune system loses tolerance to the patient's own
> intestinal
> > flora, leading to an abnormal inflammatory response that
continues
> over
> > time. The results are inflammation and ulceration in different
> areas of the
> > digestive tract, leading to the symptoms. The disease progresses
in
> the form
> > of unpredictable and variable outbreaks throughout the patient's
> life and
> > the severity of the symptoms varies according to the level of
> involvement of
> > the intestines and the patient's response to the assigned
> treatment. It is a
> > disease that usually affects young people between the ages of 18
> and 40
> > years, and approximately 2000 new cases are diagnosed in Spain
> every year.
> > Diagnosis is often difficult because it presents symptoms similar
> to those
> > of other diseases of the digestive tract: abdominal pain,
diarrhea,
> > vomiting, nausea, fever, general malaise, etc. Patients' quality
of
> life is
> > conditioned by the severity of the disease and, in the most
severe
> cases,
> > prevents them from leading a normal life, with a very high level
of
> > suffering due to the acuteness and frequency of the intestinal
> symptoms.
> >
> > Hospital Clínic de Barcelona is one of the few hospitals in the
> world to
> > instate cellular therapy using autologous stem-cell
> transplantation. In the
> > US, the treatment has been tested on 12 patients with severe
Crohn's
> > disease, of whom 11 have had very good results; in Italy, the
> treatment has
> > been applied to 4 patients, 3 of whom are also showing excellent
> progress
> > following the transplant. As Hospital Clínic, 6 patients with
> Crohn's
> > disease are already included in the process and, following the
> international
> > examples, increasing numbers of patients are expected to choose
> this option
> > to treat the disease in a state that was, to date, practically
> untreatable.
> >
> > In severe cases involving recurrent outbreaks (reactivation of
the
> disease
> > several times throughout the patient's life), Crohn's disease
> presents
> > several treatment options. Firstly, doctors choose to use
> corticosteroids
> > and immunosuppressant and biological drugs to control the
> inflammatory
> > process and prevent complications of the disease such as stenosis
> (narrowing
> > of the intestinal lumen) or fistulas (openings from the
intestinal
> lumen to
> > other organs, such as the intestine, bladder, vagina, or skin).
> However,
> > over the course of the disease, as much as 70% of severe patients
> require
> > surgery to remove segments affected by the disease, due to
failure
> of the
> > pharmacologic approach. The surgery is occasionally very
aggressive
> for the
> > patient, as it is sometimes necessary to remove the entire colon
or
> large
> > sections of the small intestine, thereby considerably affecting
the
> > absorption of food by the intestine, with a resulting
deterioration
> in
> > quality of life and body image (colostomy bag). For this reason,
new
> > treatments are being developed for patients in whom this solution
> has not
> > been an option to date.
> >
> > Autologous Stem-Cell Transplant: Phases of the Procedure
> >
> > When the case is detected (that does not respond to drugs or
> surgery), the
> > patient undergoes an autologous stem-cell transplant, which is a
> bone-morrow
> > transplant in which the immune system is reset to prevent it from
> attacking
> > the intestinal flora. The process lasts approximately 2 months
and
> consists
> > of 6 phases:
> >
> > 1. Initial Chemotherapy (Cyclophosphamide + G-CSF). In this
> initial
> > phase, leukopenia or reduction of the number of leukocytes
(immune-
> system
> > cells) in the blood is induced in the patient.
> > 2. Migration of Stem-Cells to the Blood. Following the previous
> > immunosuppression, the organism reacts by releasing stem cells
from
> the bone
> > marrow into the blood; these are the cells which will later be
used
> for the
> > transplant.
> > 3. Collection of Stem Cells by means of Apheresis. Apheresis is a
> > technique that separates components of the blood. Here, the stem
> cells that
> > previously migrated from the bone marrow are separated.
> > 4. Cryopreservation of Stem Cells. When the stem cells have been
> > collected by apheresis, they are frozen and preserved until ready
> for
> > transplant.
> > 5. Second Chemotherapy. In this phase, total leukopenia is
> induced;
> > that is, the immune system is left devoid of leukocytes, ready to
> be reset
> > with the stem-cell transplant.
> > 6. Autologous Stem-Cell Transplant. The patient receives the
> transplant
> > by means of transfusion with his or her own stem cells. The
immune
> system is
> > reset, leading to remission or reduction of the abnormal
> inflammatory
> > process of Crohn's disease.
> >
>

did you guys see they also are doing autologous fat for MS in Costa
Rica?

http://www.youtube.com/watch?v=k3Z1J3QmYoE



--- In stemcellsafety@yahoogroups.com, "Kirshner Ross-Vaden"
<kirsh@...> wrote:
>
>
> Stem Cell Treatment For Crohn's Disease
>
>
> Article Date: 21 Feb 2009 - 0:00 PST
>
>
>
>   _____
>
>
> Cellular therapy with stem cells
>
<http://www.medicalnewstoday.com/info/stem_cell/whatarestemcells.php>
  is
> revolutionizing the focus of treatment of many serious diseases.
Replacing
> the cells of damaged tissue with other new cells from the same
patient is
> already a reality. This is the basis of cellular therapy and
regenerative
> medicine, the latest great advance in biomedicine. In this line,
Hospital
> Clínic, Barcelona is leading the world in the application of an
innovative
> cellular therapy that uses stem cells to treat Crohn's disease, a
chronic
> genetic disease that affects 1% of the population in Spain and
which has
> considerable impact on the quality of life of the patients. The
procedure is
> based on an autologous bone-marrow transplant (when patients
receive a
> transplant of their own stem cells) and now constitutes a treatment
option
> to cure an intestinal disease that sometimes does not successfully
respond
> to drugs and requires highly complex surgery that does not provide
a cure.
>
> Hospital Clínic, Barcelona is one of the few hospitals in the world
to apply
> this new therapeutic option for patients with Crohn's disease, and
it does
> so with the guarantee of success experienced in the US and Italy,
where the
> technique has been tested with excellent results: in an average
follow-up
> period of 6 years, 80% of transplant patients are in a phase of
total
> remission of the disease and the remaining 20% have shown
considerable
> improvement following the transplant, and are now responding
favorably to
> drugs. Dr. Julián Panés and Dr. Elena Ricart over the
Gastroenterology
> Department of Hospital Clínic, Barcelona are the driving force
behind this
> therapy in Spain and began to implement regenerative cellular
therapy in
> patients with Crohn's disease in August 2008. To date, a total of 6
patients
> are benefiting from this new treatment, of whom 3 I've already
completed the
> process and are in the follow-up face, and a further 3 are at
different
> stages of therapy. The transplant requires several weeks of
admission to
> hospital before patients receive their own cells.
>
> The success of autologous stem-cell transplants in Crohn's disease
is
> possible thanks to the joint collaboration of the gastroenterology
and
> hematology departments and of the hemotherapy and hemostasis
department, as
> the procedure is the same as that carried out in bone-morrow
transplants to
> cure leukemia or myeloma. Thus, when a case is detected, the
professionals
> from the different departments of Hospital Clinic, Barcelona
supervise each
> of the phases of the process to autologous Transplant. In this
case, Dr.
> Panés and Dr. Ricart from the gastroenterology department work
together with
> Dr. Montserrat Rovira from the hematology department of the Catalan
hospital
> and with Dr. Enric Carreras, the head of this department, to
provide joint
> monitoring of the patients. Dr. Pedro Marín of the hemotherapy and
> hemostasis department of Hospital Clínic, together with Dr. Miquel
Lozano,
> are responsible for guiding the patients through the process of
> cryopreservation and collection of stem cells before the final
transplant.
>
> Cellular Therapy as a Strategy to Combat Crohn's Disease
>
> Crohn's disease, together with ulcerative colitis, is included in
what is
> called irritable bowel disease. It is a chronic genetic disease
that occurs
> when the immune system loses tolerance to the patient's own
intestinal
> flora, leading to an abnormal inflammatory response that continues
over
> time. The results are inflammation and ulceration in different
areas of the
> digestive tract, leading to the symptoms. The disease progresses in
the form
> of unpredictable and variable outbreaks throughout the patient's
life and
> the severity of the symptoms varies according to the level of
involvement of
> the intestines and the patient's response to the assigned
treatment. It is a
> disease that usually affects young people between the ages of 18
and 40
> years, and approximately 2000 new cases are diagnosed in Spain
every year.
> Diagnosis is often difficult because it presents symptoms similar
to those
> of other diseases of the digestive tract: abdominal pain, diarrhea,
> vomiting, nausea, fever, general malaise, etc. Patients' quality of
life is
> conditioned by the severity of the disease and, in the most severe
cases,
> prevents them from leading a normal life, with a very high level of
> suffering due to the acuteness and frequency of the intestinal
symptoms.
>
> Hospital Clínic de Barcelona is one of the few hospitals in the
world to
> instate cellular therapy using autologous stem-cell
transplantation. In the
> US, the treatment has been tested on 12 patients with severe Crohn's
> disease, of whom 11 have had very good results; in Italy, the
treatment has
> been applied to 4 patients, 3 of whom are also showing excellent
progress
> following the transplant. As Hospital Clínic, 6 patients with
Crohn's
> disease are already included in the process and, following the
international
> examples, increasing numbers of patients are expected to choose
this option
> to treat the disease in a state that was, to date, practically
untreatable.
>
> In severe cases involving recurrent outbreaks (reactivation of the
disease
> several times throughout the patient's life), Crohn's disease
presents
> several treatment options. Firstly, doctors choose to use
corticosteroids
> and immunosuppressant and biological drugs to control the
inflammatory
> process and prevent complications of the disease such as stenosis
(narrowing
> of the intestinal lumen) or fistulas (openings from the intestinal
lumen to
> other organs, such as the intestine, bladder, vagina, or skin).
However,
> over the course of the disease, as much as 70% of severe patients
require
> surgery to remove segments affected by the disease, due to failure
of the
> pharmacologic approach. The surgery is occasionally very aggressive
for the
> patient, as it is sometimes necessary to remove the entire colon or
large
> sections of the small intestine, thereby considerably affecting the
> absorption of food by the intestine, with a resulting deterioration
in
> quality of life and body image (colostomy bag). For this reason, new
> treatments are being developed for patients in whom this solution
has not
> been an option to date.
>
> Autologous Stem-Cell Transplant: Phases of the Procedure
>
> When the case is detected (that does not respond to drugs or
surgery), the
> patient undergoes an autologous stem-cell transplant, which is a
bone-morrow
> transplant in which the immune system is reset to prevent it from
attacking
> the intestinal flora. The process lasts approximately 2 months and
consists
> of 6 phases:
>
> 1. Initial Chemotherapy (Cyclophosphamide + G-CSF). In this
initial
> phase, leukopenia or reduction of the number of leukocytes (immune-
system
> cells) in the blood is induced in the patient.
> 2. Migration of Stem-Cells to the Blood. Following the previous
> immunosuppression, the organism reacts by releasing stem cells from
the bone
> marrow into the blood; these are the cells which will later be used
for the
> transplant.
> 3. Collection of Stem Cells by means of Apheresis. Apheresis is a
> technique that separates components of the blood. Here, the stem
cells that
> previously migrated from the bone marrow are separated.
> 4. Cryopreservation of Stem Cells. When the stem cells have been
> collected by apheresis, they are frozen and preserved until ready
for
> transplant.
> 5. Second Chemotherapy. In this phase, total leukopenia is
induced;
> that is, the immune system is left devoid of leukocytes, ready to
be reset
> with the stem-cell transplant.
> 6. Autologous Stem-Cell Transplant. The patient receives the
transplant
> by means of transfusion with his or her own stem cells. The immune
system is
> reset, leading to remission or reduction of the abnormal
inflammatory
> process of Crohn's disease.
>

Report: Fetal stem cells trigger tumors in ill boy
WASHINGTON—A family desperate to save a child from a lethal brain
disease sought highly experimental injections of fetal stem cells—
injections that triggered tumors in the boy's brain and spinal cord,
Israeli scientists reported Tuesday.
Scientists are furiously trying to harness different types of stem
cells—the building blocks for other cells in the body—to regrow
damaged tissues and thus treat devastating diseases. But for all the
promise, researchers have long warned that they must learn to control
newly injected stem cells so they don't grow where they shouldn't,
and small studies in people are only just beginning.

Tuesday's report in the journal PLoS Medicine is the first documented
case of a human brain tumor—albeit a benign, slow-growing one—after
fetal stem cell therapy, and hammers home the need for careful
research. The journal is published by the Public Library of Science.

"Patients, please beware," said Dr. John Gearhart, a stem cell
scientist at the University of Pennsylvania who wasn't involved in
the Israeli boy's care but who sees similarly desperate U.S. patients
head abroad to clinics that offer unproven stem cell injections.

"Cells are not drugs. They can misbehave in so many different ways,
it just is going to take a good deal of time" to prove how best to
pursue the potential therapy, Gearhart said.

The unidentified Israeli boy has a rare, fatal genetic disease with a
tongue-twisting name—ataxia telangiectasia, or A-T. Degeneration of a
certain brain region gradually robs these children of movement. Plus,
a faulty immune system leads to frequent infections and cancers. Most
die in their teens or early 20s.

Israeli doctors pieced together the child's history: When he was 9,
the family traveled to Russia, to a Moscow clinic that provided
injections of neural stem cells from fetuses—immature cells destined
to grow into a main type of brain cells. The cells were injected into
his brain and spinal cord twice more, at ages 10 and 12.

Back home in Israel at age 13, the boy's A-T was severe enough to
require that he use a wheelchair when he also began complaining of
headaches. Tests at Sheba Medical Center in Tel Aviv uncovered a
growth pushing on his brain stem and a second on his spinal cord.
Surgeons removed the spinal cord mass when the boy was 14, in 2006
and they say his general condition has remained stable since then.

But was the boy prone to tumors anyway or were the fetal stem cells
to blame? A Tel Aviv University team extensively tested the tumor
tissue and concluded it was the fetal cells. Among other evidence,
some of the cells were female and had two normal copies of the gene
that causes A-T—although that boy's underlying poor immune function
could have allowed the growths to take hold.

Using stem cells from multiple fetuses that also were mixed with
growth-spurring compounds "may have created a high-risk situation
where abnormal growth of more than one cell occurred," wrote lead
researcher Dr. Ninette Amariglio of Sheba Medical. She urged better
research to "maximize the potential benefits of regenerative medicine
while minimizing the risks."

This brain disease wasn't conducive to stem cell therapy in the first
place, said stem cell specialist Dr. Marius Wernig of Stanford
University, who said it's unclear exactly what was implanted.

"Stem cell transplantations have a humongous potential," Wernig said.
But "if people rush out there without really knowing what they're
doing ... that really backfires and can bring this whole field to a
halt."